

<u>Rituximab</u>: Rituxan<sup>®</sup>, Truxima<sup>®</sup>, Ruxience<sup>™</sup>, Riabni<sup>™</sup> (Intravenous)



Last Review Date: 06/04/2024 Date of Origin: 06/03/2019 Dates Reviewed: 06/2019, 10/2019, 11/2019, 01/2020, 04/2020, 07/2020, 10/2020, 01/2021, 04/2021, 07/2021, 10/2021, 01/2022, 04/2022, 07/2022, 10/2022, 01/2023, 04/2023, 07/2023, 10/2023, 01/2024, 04/2024, 06/2024

# I. Length of Authorization <sup>1-5,23-25,34,44,62,80,94-98,102-104,108,115-118,128-130,133-138,153,155,170-174</sup>

Coverage will be provided for 6 months (12 months initially for pemphigus vulgaris) and may be renewed, unless otherwise specified.

- Maintenance therapy for oncology indications may be renewed for up to a maximum of 2 years, unless otherwise specified:
  - Adult Acute Lymphoblastic Leukemia (ALL) may be renewed for a maximum of 18 doses.
  - Mantle Cell Lymphoma may be renewed until disease progression or intolerable toxicity.
  - Hairy Cell Leukemia may be renewed for up to a maximum of 12 doses.
  - Induction/Consolidation of Pediatric B-Cell Acute Leukemia and Aggressive Mature B-Cell Lymphomas may NOT be renewed.
- Management of Immunotherapy-Related Toxicities:
  - Myositis/Myasthenia Gravis/Encephalitis may NOT be renewed.
  - Bullous dermatitis may be renewed for a maximum of 18 months (4 total doses).
- Relapse therapy for Pemphigus Vulgaris must be at least 16 weeks past a prior infusion
- Chronic Graft-Versus-Host Disease (cGVHD) may NOT be renewed.
- Hematopoietic Cell Transplantation may NOT be renewed.
- Lupus Nephritis and Pediatric Idiopathic Nephrotic Syndrome may be renewed ONLY in patients experiencing a disease relapse.
- Complications of Transplanted Solid Organ may NOT be renewed.



#### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [NDC Unit]:

- Rituxan 100 mg/10 mL single-dose vial for injection: 12 vials per 28 day supply
- Rituxan 500 mg/50 mL single-dose vial for injection: 8 vials per 28 day supply
- Truxima 100 mg/10 mL single-dose vial for injection: 12 vials per 28 day supply
- Truxima 500 mg/50 mL single-dose vial for injection: 8 vials per 28 day supply
- Ruxience 100 mg/10 mL single-dose vial for injection: 12 vials per 28 day supply
- Ruxience 500 mg/50 mL single-dose vial for injection: 8 vials per 28 day supply
- Riabni 100 mg/10 mL single-dose vial for injection: 12 vials per 28 day supply
- Riabni 500 mg/50 mL single-dose vial for injection: 8 vials per 28 day supply

#### B. Max Units (per dose and over time) [HCPCS Unit]:

Oncology Indications
Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL):
• Initial therapy:
• Loading dose: 100 billable units x 1 dose
• Subsequent doses: 130 billable units every 28 days x 5 doses per 6 months
• Renewal therapy: 130 billable units every 8 weeks
ALL
• 100 billable units twice weekly x 18 doses
Hairy Cell Leukemia
• 100 billable units weekly x 8 doses, 100 billable units every 14 days x 8 doses, then
100 billable units every 28 days x 4 doses
Chronic Graft-Versus-Host Disease (cGVHD)
• 100 billable units weekly x 8 doses
Hematopoietic Cell Transplantation
• Initial dose: 100 billable units x 1 dose before transplant
• Subsequent doses: 250 billable units x 3 doses after transplant
All other oncology indications:
• Initial therapy: 100 billable units weekly x 8 doses per 6 months
• Renewal therapy: 100 billable units x 4 doses per 6 months
Non-Oncology Indications
Rheumatoid Arthritis (RA):
• 100 billable units every 14 days x 2 doses in an 18-week period
Multiple Sclerosis (MS):
• 100 billable units every 14 days x 2 doses every 6 months
Pemphigus Vulgaris (PV):
• Initiation: 100 billable units weekly x 4 doses in a 12 month period
• Maintenance and Relapse: 50 billable units every 16 weeks
GPA(WG)/MPA:
• Induction: 100 billable units weekly x 4 doses in a 20-week period
• Initial Maintenance: 100 billable units x 2 doses in a 6 month period
• Subsequent Maintenance: 100 billable units every 6 months
All other non-oncology indications:
• 100 billable units weekly x 4 doses in a 6 month period



#### III. Initial Approval Criteria<sup>1-4</sup>

Coverage is provided in the following conditions:

- Patient must try and have an inadequate response, contraindication, or intolerance to Riabni<sup>™</sup> (rituximab- arrx) OR Truxima<sup>®</sup> (rituximab-abbs) prior to the consideration of another rituximab product; **AND**
- Patient age is at least 18 years of age, unless otherwise specified; AND

#### Universal Criteria 1-4

- Patient does not have a severe, active infection; AND
- Patient has been screened for the presence of hepatitis B (HBV) infection (i.e., HBsAg and anti-HBc) prior to initiating therapy and patients with evidence of current or prior HBV infection will be monitored for HBV reactivation during treatment; **AND**
- Patient has not received a live vaccine within 28 days prior to starting treatment and live vaccines will not be administered concurrently while on treatment; **AND**

#### **Oncology Indications** 1-5

• Patient is CD20 antigen expression positive (excluding use for cGVHD, Hematopoietic Cell Transplantation, and Management of Immunotherapy-Related Toxicity); AND

#### Pediatric Mature B-Cell Acute Leukemia (B-AL) † $\Phi$ <sup>1</sup>

- Patient is at least 6 months of age; AND
- Used in combination with chemotherapy for previously untreated disease

#### Adult\* Acute Lymphoblastic Leukemia (ALL) ‡ 5,93

- Patient has Philadelphia chromosome-negative (Ph-) disease; AND
  - $\circ$  Used for induction/consolidation therapy; AND
  - Used as a component of a multiagent chemotherapy

\*NCCN recommendations for Adult ALL may be applicable to adolescent and young adult (AYA) patients within the age range of 15-39 years.

#### Central Nervous System (CNS) Cancers ‡ <sup>5,15,44,9e</sup>

- Patient has primary CNS lymphoma; AND
- Used for induction therapy in combination with a methotrexate-containing regimen

#### Adult Hodgkin Lymphoma ‡ <sup>5,82,83</sup>

• Patient has nodular lymphocyte-predominant disease



Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)  $\dagger \ddagger \Phi$  <sup>1-5,23e,24e,28e-30e,38e,42e,43e,45e,61e,161e</sup>

- Used in combination with fludarabine and cyclophosphamide (FC) **†**; **AND** 
  - Used as first-line therapy in patients < 65 years of age; **OR**
  - $\circ$  Used as subsequent therapy; **OR**
- Patient has disease without del(17p)/TP53 mutation; AND
  - Used as first-line therapy in combination with bendamustine *(excluding use in frail patients)*, **OR**
  - Used as subsequent therapy in combination with one of the following:
    - Bendamustine (patients <65 years of age without significant comorbidities; excluding use in frail patients)
    - Idelalisib
    - Lenalidomide
    - Venetoclax; AND

In combination with lenalidomide ONLY:

- Patient must demonstrate an inadequate response to one of the following regimens, unless there is a contraindication or intolerance, prior to approval of rituximab in combination with lenalidomide:
  - Idelalisib + rituximab
  - Bendamustine + rituximab (patients <65 years of age without significant comorbidities)</p>
  - FCR (fludarabine, cyclophosphamide, rituximab) (patients <65 years without significant comorbidities); OR</li>
- Patient has disease <u>with</u> del(17p)/TP53 mutation; **AND** 
  - Used as subsequent therapy in combination with one of the following:
    - Idelalisib
    - Lenalidomide
    - Venetoclax; AND

In combination with lenalidomide ONLY:

- Patient must demonstrate an inadequate response to idelalisib + rituximab, unless there is a contraindication or intolerance, prior to approval of rituximab in combination with lenalidomide; OR
- Used as initial therapy for histologic (Richter's) transformation to diffuse large B-cell lymphoma; **AND** 
  - Used in combination with cyclophosphamide, doxorubicin, and vincristine-based regimens or as a component of OFAR (oxaliplatin, fludarabine, cytarabine, and rituximab)



#### Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma ‡ <sup>5,67e,72e</sup>

Adult B-Cell Lymphomas  $\dagger \ddagger \Phi^{1-5,44}$  including, but not limited to, the following:

- HIV-Related B-Cell Lymphomas **‡** 
  - Disease is related to Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), HHV-8 positive DLBCL (not otherwise specified), or primary effusion lymphoma (PEL)
- Burkitt Lymphoma **‡** 
  - $\circ$  Used in combination with chemotherapy
- Diffuse Large B-Cell Lymphoma †  $\Phi$
- Low-Grade (grade 1-2) or Follicular Lymphoma  $\dagger \Phi$
- Extranodal Marginal Zone Lymphoma (EMZL) of the Stomach & Nongastric Sites (Noncutaneous) **‡**
- Nodal & Splenic Marginal Zone Lymphoma ‡
- High-Grade B-Cell Lymphomas **‡**
- Mantle Cell Lymphoma **‡**
- Histologic Transformation of Indolent Lymphomas to Diffuse Large B-Cell Lymphoma **‡**
- Post-Transplant Lymphoproliferative Disorders (PTLD) (B-Cell type) **‡**

#### Castleman Disease ‡ <sup>5</sup>

• Patient has multicentric disease

# Pediatric Aggressive Mature B-Cell Lymphomas (Primary Mediastinal Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma, & Burkitt-like Lymphoma) † $\Phi$ <sup>1,5,50,121</sup>

- Patient is at least 6 months of age\*; AND
- Used in combination with chemotherapy

\*Pediatric Aggressive Mature B-Cell Lymphoma may be applicable to adolescent and young adult (AYA) patients older than 18 years of age and less than 39 years of age, who are treated in the pediatric oncology setting.

# Hairy Cell Leukemia ‡ <sup>5</sup>

- Used as a single agent; AND
  - Used for less than complete response or relapsed disease in patients unable to receive purine analogs (i.e., cladribine or pentostatin); **OR**
- Used in combination with cladribine; **OR**
- Used in combination with vemurafenib; AND
  - Used for less than complete response or relapse disease within 2 years of complete response following initial treatment with cladribine or pentostatin; **OR**



Used for progression <u>after</u> therapy for relapsed or refractory disease (if not previously given)

### Chronic Graft-Versus-Host Disease (cGVHD) ‡ 5,22-25,45

- Patient is post-allogeneic hematopoietic cell transplant (generally 3 or more months); AND
- Used as additional therapy in combination with systemic corticosteroids; AND
- Patient has no response (e.g., steroid-refractory disease) to first-line therapy options

# Hematopoietic Cell Transplantation (HCT) ‡ <sup>5</sup>

• Used as conditioning for allogeneic transplant as part of a non-myeloablative regimen in combination with cyclophosphamide and fludarabine

# Management of Immunotherapy-Related Toxicities ‡ 5,62

- Patient has been receiving therapy with an immune checkpoint inhibitor (e.g., cemiplimab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, ipilimumab, dostarlimab, nivolumab/relatlimab, tremelimumab, retifanlimab, toripalimab, etc.); **AND** 
  - $\circ$  Patient has encephalitis related to immunotherapy; AND
    - Patient is autoimmune-encephalopathy-antibody positive; **OR**
    - Patient has had limited to no improvement after 7 to 14 days on high-dose corticosteroids with or without intravenous immunoglobulin (IVIG); OR
  - Patient has bullous dermatitis related to immunotherapy; **AND** 
    - Used as additional therapy for moderate (G2), severe (G3) or life-threatening (G4) disease; **OR**
  - Patient has moderate, severe, or life-threatening steroid-refractory myositis (proximal muscle weakness, neck flexor weakness, with or without myalgias) related to immunotherapy; AND
    - Used for significant dysphagia, life-threatening situations, or cases refractory to corticosteroids; **OR**
  - Patient has myasthenia gravis related to immunotherapy; AND
    - Used as additional therapy for severe (G3-4) disease that is refractory to plasmapheresis or IVIG

# **Non-Oncology Indications**

• Patient is not on concurrent treatment with another CD20-directed therapy, TNF-inhibitor, IL-inhibitor, biologic response modifier or other non-biologic agent (e.g., apremilast, abrocitinib, tofacitinib, baricitinib, upadacitinib, deucravacitnib, etc.); **AND** 

#### Rheumatoid Arthritis (RA) † 1-4,46-49,112,113

• Physician has assessed baseline disease severity utilizing an objective measure/tool; AND



- Documented moderate to severe active disease; AND
- Used in combination with methotrexate unless the patient has a contraindication or intolerance;  $\ensuremath{\textbf{AND}}$
- Patient tried and failed at least a 3-month trial with ONE oral disease modifying antirheumatic drug (DMARD) (e.g., methotrexate, azathioprine, auranofin, hydroxychloroquine, penicillamine, sulfasalazine, leflunomide, etc.)\*; **AND**
- Previous failure with one or more preferred TNF antagonists at least one of which should be a self-injectable; **AND**
- Patient has not had treatment with rituximab in the previous 4 months

\* Note: For patients already established on biologic therapy, trial and failure of oral DMARDs is not required.

# Pemphigus Vulgaris † $\Phi^{1,10,11,35,36,38,61,80,114,139}$

- Patient has a diagnosis of pemphigus vulgaris as determined by the following:
  - Patient has one or more of the following clinical features:
    - Appearance of lesions, erosions and/or blisters
    - Nikolsky sign (induction of blistering via mechanical pressure at the edge of a blister or on normal skin)
    - Characteristic scarring and lesion distribution; AND
  - Histopathologic confirmation by skin/mucous membrane biopsy; AND
  - Positive direct immunofluorescence (DIF) microscopy result OR the presence of autoantibodies as detected by indirect immunofluorescence (IIF) or enzyme-linked immunosorbent assay (ELISA); AND
- Patient has moderate to severe disease as assessed utilizing an objective measure/tool (e.g., PDAI, PSS, ABSIS, etc.); **AND**
- Used in combination with glucocorticoids (e.g., prednisone, prednisolone, etc.); AND
- Other causes of blistering or erosive skin and mucous membrane diseases have been ruled out

# Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) † $\Phi$ <sup>1-4,125</sup>

- Patient is at least 2 years of age; AND
- Used in combination with glucocorticoids (e.g., prednisone, methylprednisolone, etc.)

# Thrombocytopenic Purpura ‡ 6-9,63,127

- Diagnosis includes one of the following:
  - Primary thrombocytopenia or Idiopathic (Immune) thrombocytopenia purpura (ITP)
  - Evans syndrome; AND



- Patient has previously failed or has a contraindication or intolerance to therapy with corticosteroids; **AND**
- Patient is at increased risk for bleeding as indicated by platelet count (within the previous 28 days) of less than  $30 \times 10^{9}$ /L (30,000/mm<sup>3</sup>)

#### Thrombotic Thrombocytopenic Purpura (TTP) ‡ 16-18,20,21,126

- Patient has immune-mediated or acquired disease with ADAMTS13-deficiency; AND
  - $\circ$  Used in combination with corticosteroids and the rapeutic plasma exchange (TPE); **OR**
  - Used as a single agent as prophylactic therapy for patients in remission

#### Multiple Sclerosis (MS) <sup>‡</sup> <sup>144,148</sup>

- Patient must have a confirmed diagnosis of multiple sclerosis (MS) as documented by laboratory report (i.e., MRI); **AND**
- Patient has a diagnosis of a relapsing form of MS [i.e., relapsing-remitting MS (RRMS)\*, active secondary progressive disease (SPMS)\*\*, or clinically isolated syndrome (CIS)\*\*\*]

\*Definitive diagnosis of MS with a relapsing-remitting course is based upon <u>BOTH</u> dissemination in time and space. Unless contraindicated, MRI should be obtained (even if criteria are met). <sup>148</sup>

	<u>Dissemination in time</u> (Development/appearance of new CNS lesions over time)	<u>Dissemination in space</u> (Development of lesions in distinct anatomical locations within the CNS; multifocal)
•	<ul> <li>2 clinical attacks; OR</li> <li>1 clinical attack <u>AND</u> one of the following:</li> <li>MRI indicating simultaneous presence of gadolinium-enhancing and non-enhancing lesions at any time or by a new T2-hyperintense or gadolinium-enhancing lesion on follow-up MRI compared to baseline</li> </ul>	<ul> <li>≥ 2 lesions; OR</li> <li>1 lesion <u>AND</u> one of the following:         <ul> <li>Clear-cut historical evidence of a previous attack involving a lesion in a distinct anatomical location</li> <li>MRI indicating ≥ 1 T2-hyperintense lesions characteristic of MS in ≥ 2 of 4 areas of the CNS (periventricular, cortical or juxtacortical, infratentorial, or spinal cord)</li> </ul> </li> </ul>
	<ul> <li>CSF-specific oligoclonal bands</li> </ul>	

\*\*Active secondary progressive MS (SPMS) is defined as the following: <sup>145,148-150</sup>

• Expanded Disability Status Scale (EDSS) score  $\geq$  3.0; **AND** 

Disease is progressive ≥ 3 months following an initial relapsing-remitting course (i.e., EDSS score increase by 1.0 in patients with EDSS ≤5.5 or increase by 0.5 in patients with EDSS ≥6);
 AND

- $\circ \quad \geq 1$  relapse within the previous 2 years;  $\mathbf{OR}$
- Patient has gadolinium-enhancing activity OR new or unequivocally enlarging T2 contrastenhancing lesions as evidenced by MRI

#### \*\*\*Definitive diagnosis of CIS is based upon <u>ALL</u> of the following: <sup>148</sup>

• A monophasic clinical episode with patient-reported symptoms and objective findings reflecting a focal or multifocal inflammatory demyelinating event in the CNS

		RITUXIMAB -E- (Rituxan®, Truxima®, Ruxience®, Riabni™)
		Prior Auth Criteria
Page 8	- I -	Proprietary Information. Restricted Access – Do not disseminate or copy
		without approval.
		©2024, Magellan Rx Management



- Neurologic symptom duration of at least 24 hours, with or without recovery
- Absence of fever or infection
- Patient is not known to have multiple sclerosis

#### Autoimmune Hemolytic Anemia (AIHA) ‡ <sup>26-32</sup>

- Patient has warm-reactive disease refractory to or dependent on glucocorticoids; OR
- Patient has cold agglutinin disease with symptomatic anemia, transfusion-dependence, and/or disabling circulatory symptoms

#### Systemic Lupus Erythematosus (SLE) ‡ <sup>153-155,158-163,169</sup>

- Patient has a confirmed diagnosis of SLE as evidenced by all of the following:
  - Confirmed SLE classification criteria score ≥ 10\* (Note: must include clinical and immunologic domains criteria)
  - Anti-nuclear antibody (ANA) titer of ≥ 1:80 measured via indirect immunofluorescence (IIF) on human epithelial (HEp-2) cells (or an equivalent ANA positive test) at least once; AND
- Patient has failed to respond adequately to at least two (2) standard therapies such as antimalarials (i.e. hydroxychloroquine, chloroquine), corticosteroids, non-steroidal antiinflammatory drugs (NSAIDs), aspirin, immunosuppressives (i.e. azathioprine, methotrexate, calcineurin inhibitors [cyclosporine, tacrolimus, voclosporin], oral cyclophosphamide, or mycophenolate)\*\*; AND
- Patient has moderate to severe active disease defined as a Physician's Global Assessment (PGA) score of > 1 AND one of the following:
  - Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K) score of  $\geq 6$
  - Disease activity with ≥ 2 systems with British Isles Lupus Assessment Group-2004 (BILAG) B scores

*Classification Criteria for Systemic Lupus Erythematosus (SLE)		
Clinical Score $\Delta$	Clinical Domains and Criteria	
(range: 0-39)		
2	<b>Constitutional:</b> Unexplained fever > 101°F	
	Hematologic:	
3	White blood cell count < 4,000/mm <sup>3</sup>	
4	Platelet count < 100,000/mm <sup>3</sup> or Autoimmune hemolysis	
	Neuropsychiatric:	
2	Delirium	
3	Psychosis	
5	Primary generalized seizure or partial/focal seizure	
	Mucocutaneous +:	
2	Non-scarring alopecia or oral ulcers	
4	Subacute cutaneous or discoid lupus	
6	Acute cutaneous lupus	
	Serosal:	

 $- \geq 1$  system(s) with British Isles Lupus Assessment Group-2004 (BILAG) A score(s)



5	Pleural or pericardial effusion
0	
6	Acute pericarditis
	Musculoskeletal:
6	Joint involvement with either synovitis involving 2 or more joints with
	swelling or effusion OR tenderness in 2 or more joints with at least 30
	minutes of morning stiffness
	Renal:
4	Proteinuria > 0.5g/24 hr by a 24-hour urine or equivalent spot urine
	protein-to-creatinine ratio
8	Renal biopsy class II or V lupus nephritis
10	Renal biopsy Class III or IV lupus nephritis
Immunologic Score <sup>A</sup>	
Immunologic Score <sup>A</sup>	Immunologio Domoing and Critario
Immunologic Score △ (range: 0-12)	Immunologic Domains and Criteria
Immunologic Score △ (range: 0-12) 2	Immunologic Domains and Criteria Presence of antiphospholipid antibodies (i.e., positive lupus anticoagulant,
Immunologic Score △ (range: 0-12) 2	Immunologic Domains and Criteria Presence of antiphospholipid antibodies (i.e., positive lupus anticoagulant, positive anti-82GP1 antibodies, and/or anti-cardiolipin antibodies at
Immunologic Score △ (range: 0-12) 2	Immunologic Domains and Criteria Presence of antiphospholipid antibodies (i.e., positive lupus anticoagulant, positive anti-82GP1 antibodies, and/or anti-cardiolipin antibodies at medium or high titer)
Immunologic Score △ (range: 0-12) 2	Immunologic Domains and Criteria           Presence of antiphospholipid antibodies (i.e., positive lupus anticoagulant, positive anti-82GP1 antibodies, and/or anti-cardiolipin antibodies at medium or high titer)           Presence of low complement proteins (below lower limit of normal):
Immunologic Score △ (range: 0-12) 2 3	Immunologic Domains and CriteriaPresence of antiphospholipid antibodies (i.e., positive lupus anticoagulant, positive anti-82GP1 antibodies, and/or anti-cardiolipin antibodies at medium or high titer)Presence of low complement proteins (below lower limit of normal): Low C3 OR low C4
Immunologic Score △ (range: 0-12) 2 3 4	Immunologic Domains and Criteria         Presence of antiphospholipid antibodies (i.e., positive lupus anticoagulant, positive anti-β2GP1 antibodies, and/or anti-cardiolipin antibodies at medium or high titer)         Presence of low complement proteins (below lower limit of normal):         Low C3 OR low C4         Low C3 AND C4
<b>Immunologic Score </b> △ (range: 0-12) 2 3 4 6	Immunologic Domains and CriteriaPresence of antiphospholipid antibodies (i.e., positive lupus anticoagulant, positive anti-82GP1 antibodies, and/or anti-cardiolipin antibodies at medium or high titer)Presence of low complement proteins (below lower limit of normal): Low C3 OR low C4 Low C3 AND C4Presence of anti-Sm and/or anti-dsDNA antibodies
Immunologic Score △ (range: 0-12) 2 3 4 6 * A web-based scoring	Immunologic Domains and CriteriaPresence of antiphospholipid antibodies (i.e., positive lupus anticoagulant, positive anti-62GP1 antibodies, and/or anti-cardiolipin antibodies at medium or high titer)Presence of low complement proteins (below lower limit of normal): Low C3 OR low C4 Low C3 AND C4Presence of anti-Sm and/or anti-dsDNA antibodiescalculator as well as further definitions of each criterion are available at:

<sup>A</sup>Occurrence on at least one occasion is sufficient to count toward score when all other causes have been ruled out. Count only the highest weighted score within each of the 10 domains (7 clinical and 3 immunologic) and any additional criteria within the same domain will not count. + Observed by a physician via clinical exam or photograph review

\*\*Note: For patients already established on biologic therapy, trial and failure of standard therapy is not required.

### Lupus Nephritis (LN) ‡ 115-117,132,153,155,159,169

- Patient has disease that is non-responsive or refractory to standard first-line therapy (i.e., mycophenolate mofetil, mycophenolic acid, cyclophosphamide, or calcineurin inhibitors [e.g., tacrolimus, voclosporin, cyclosporine etc.]); **AND**
- Used as a single agent OR as add-on therapy in combination with mycophenolate mofetil, mycophenolic acid, or cyclophosphamide

#### Myasthenia Gravis (unrelated to immunotherapy-related toxicity) ‡ <sup>118-120,156</sup>

- Patient has muscle-specific tyrosine kinase (MuSK)-antibody positive disease; AND
- Patient is refractory to standard first-line therapy (e.g., glucocorticoids, azathioprine, mycophenolate mofetil, etc.)

# Complications of Transplanted Solid Organ (kidney, liver, lung, heart, pancreas) in Adult and Pediatric\* Patients <sup>133-138</sup>

• Used for suppression of panel reactive anti-human leukocyte antigen (HLA) antibodies prior to transplantation; **OR** 



• Used for treatment of antibody-mediated rejection of solid organ transplantation

\*Note: There is no minimum age requirement for this indication

#### Neuromyelitis Optica Spectrum Disorder (NMOSD) ‡ 90-92,157,165

- Patient has a confirmed diagnosis based on the following:
  - Patient was found to be seropositive for aquaporin-4 (AQP4) IgG antibodies; AND
    - Patient has at least one core clinical characteristic § (\*Note: some core clinical characteristics require both clinical and typical MRI findings); AND
    - Alternative diagnoses have been excluded [e.g., myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOGAD), multiple sclerosis, sarcoidosis, cancer, chronic infection, etc.]; OR
  - Patient is seronegative for AQP4-IgG antibodies OR has unknown AQP4-IgG status; AND
    - Patient has at least two core clinical characteristics § occurring as a result of one or more clinical attacks; AND
    - Patient has experienced ALL of the following:
      - At least 1 core clinical characteristic must be acute optic neuritis, acute myelitis, or area postrema syndrome
      - Fulfillment of typical MRI findings requirements for each area affected  $\psi$ ; AND
    - Alternative diagnoses have been excluded [e.g., myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOGAD), multiple sclerosis, sarcoidosis, cancer, chronic infection, etc.]; AND
- Used as a single agent or in combination with immunosuppressive therapy (e.g., azathioprine, methotrexate, mycophenolate, etc.)

# § Core Clinical Characteristics of NMOSD 90,157

- Acute optic neuritis
- Acute myelitis
- Acute area postrema syndrome (APS): episode of otherwise unexplained hiccups and/or nausea and vomiting (lasting for at least 48 hours or with MRI evidence of a dorsal brainstem lesion)
- Acute brainstem syndrome other than APS
- Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic lesion on MRI ¥
- Acute cerebral syndrome with NMOSD-typical brain lesion on MRI \*\*

#### Ψ Typical MRI findings in NMOSD related to clinical presentation (T2 unless noted otherwise) <sup>157</sup>

- Optic neuritis: Normal cerebral MRI (or only nonspecific white matter lesions) OR longitudinally
  extensive optic nerve lesion (≥ half of the length of the optic nerve or involving optic chiasm; T2 or
  T1/Gd)
- Myelitis: Intramedullary lesion ≥ 3 contiguous VS (LETM) OR focal atrophy ≥ 3 contiguous VS in patients with a history of acute myelitis
- Area postrema syndrome (APS): Lesion in the dorsal medulla oblongata/area postrema
- Other brainstem syndrome: Periependymal brainstem lesion (4th ventricle)
- ¥ Diencephalic syndrome: Periependymal lesion (3rd ventricle) OR hypothalamic/thalamic lesion

RITUXIMAB -E- (Rituxan<sup>®</sup>, Truxima<sup>®</sup>, Ruxience<sup>®</sup>, Riabni<sup>™</sup>) Prior Auth Criteria



 \*\* Cerebral syndrome: Extensive periependymal lesion (lateral ventricle; often with Gd) OR long (> 1/2 length), diffuse, heterogeneous or edematous corpus callosum lesion OR long corticospinal tract lesion (unilateral or bilateral, contiguously involving internal capsule and cerebral peduncle) OR large, confluent (unilateral or bilateral) subcortical or deep white matter lesion

LETM = longitudinally extensive transverse myelitis lesions; VS = vertebral segments

#### Antisynthetase Syndrome-Related Interstitial Lung Disease ‡ 167,168,174

- Patient has antisynthetase antibody positive disease (e.g., anti-Jo-1, -PL-7, -PL-12, -OJ, -EJ, etc.); **AND**
- Physician has assessed baseline disease severity utilizing an objective measure (i.e., baseline glucocorticoid use, pulmonary function testing [i.e., forced vital capacity (FVC%), total lung capacity (TLC%), diffusing capacity of the lungs for carbon monoxide (DLCO%)], or chest CT scan); **AND**
- Patient has documented severe active disease; AND
- Patient has recurrent or progressive disease despite treatment with glucocorticoids and/or other immunosuppressive agents (e.g., azathioprine, mycophenolate mofetil, cyclophosphamide, tacrolimus, etc.); **AND**
- Will be used in combination with glucocorticoids or other immunosuppressive agents (e.g., azathioprine, mycophenolate mofetil, cyclophosphamide, tacrolimus, etc.), unless the patient has a contraindication or intolerance

#### Idiopathic Membranous Nephropathy ‡ 172, 175-177

- Patient has a documented diagnosis of idiopathic (primary) membranous nephropathy; AND
- Secondary causes of membranous nephropathy have been ruled out [e.g., infections, autoimmune diseases, malignancies, nutritional supplements (e.g., lipoic acid, etc.), nonsteroidal anti-inflammatory drugs (NSAIDs), etc.]; **AND** 
  - Used as first-line therapy in patients with any of the following moderate to high risk factors for progressive disease:
    - Proteinuria > 3.5 g/day and no decrease > 50% after 6 months of therapy with an angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB); OR
    - eGFR < 60 ml/min/1.73m<sup>2</sup>; **OR**
    - Proteinuria > 8 g/d for > 6 months; **OR**
    - Patient has experienced serious complications of nephrotic syndrome (e.g., acute kidney injury, infection, thromboembolic events, etc.); **OR**
  - Used for initial disease relapse following remission on first-line therapy with rituximab, a calcineurin inhibitor (e.g., tacrolimus, cyclosporine, etc.) or cyclophosphamide in combination with glucocorticoids; **OR**



- Used for treatment-resistance to first-line therapy with rituximab, a calcineurin inhibitor (e.g., tacrolimus, cyclosporine, etc.) or cyclophosphamide in combination with glucocorticoids; **AND** 
  - Patient has a stable eGFR; **AND**
  - Will be used in combination with a calcineurin inhibitor if previously treated with rituximab alone in the first-line setting; **OR**
- Used for disease recurrence following kidney transplant; AND
  - Patient has proteinuria > 1 g/d

#### Pediatric Idiopathic Nephrotic Syndrome ‡ <sup>170-173</sup>

- Patient is 12 years of age or younger; AND
- Patient has symptomatic disease (i.e., nephrotic-range proteinuria and either hypoalbuminemia or edema when albumin level is not available); **AND**
- Patient has been diagnosed with one of the following:
  - Frequently relapsing nephrotic syndrome (FRNS) with at least four relapses per year or at least two relapses within 6 months of initial presentation
  - Steroid dependent nephrotic syndrome (SDNS) with two consecutive relapses during steroid tapering or within 14 days of cessation of therapy
  - Steroid resistant nephrotic syndrome (SRNS) with failure to achieve complete remission within a 4-6 -week course of daily corticosteroids; **AND**
- Patient has failed an adequate trial with at least one other steroid-sparing agent (e.g., cyclophosphamide, calcineurin inhibitor [e.g., tacrolimus, cyclosporine, etc.], mycophenolate mofetil, etc.)

#### IgG4-Related Disease ‡ 178-182

- Physician has assessed baseline disease severity utilizing an objective measure/tool (e.g., IgG4-RD Responder Index score, physician's global assessment [PGA], amount of glucocorticoid or other immunosuppressive use, incidence of disease flares, serum IgG4 level, etc.); **AND**
- Other conditions that mimic IgG4-related disease have been ruled out (e.g., malignancy, infection, other autoimmune disorders, etc.); **AND**
- Patient has documented active disease; AND
- Documented failure or ineffective response to an adequate trial with glucocorticoids, unless there is a contraindication or intolerance to use

Preferred therapies and recommendations are determined by review of clinical evidence. NCCN category of recommendation is taken into account as a component of this review. Regimens deemed equally efficacious (i.e., those having the same NCCN categorization) are considered to be therapeutically equivalent.



 $\dagger$  FDA Approved Indication(s);  $\ddagger$  Compendia Recommended Indication(s);  $\Phi$  Orphan Drug

#### IV. Renewal Criteria <sup>1-4</sup>

Coverage may be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe infusion-related reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions (e.g., paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, etc.), progressive multifocal leukoencephalopathy (PML), hepatitis B virus reactivation, serious infections (bacterial, fungal or viral), cardiovascular adverse reactions (e.g., ventricular fibrillation, myocardial infarction, cardiogenic shock, cardiac arrhythmias), renal toxicity, bowel obstruction and perforation, etc.; **AND**

#### Oncology Indications 1-5,23-25,34,44,50,62,80,94-98,102-104,129,130,102-104,128

• Patient has not exceeded dosing or duration limits as defined in Sections I, II, and V; AND

#### Adult Acute Lymphoblastic Leukemia (ALL)

• Treatment response or stabilization of disease as indicated by CBC, bone marrow cytogenic analysis, QPCR, or FISH

# Pediatric B-Cell Acute Leukemia and Aggressive Mature B-Cell Lymphomas (induction or consolidation therapy)

• Coverage may NOT be renewed

#### Chronic Graft-Versus-Host Disease (cGVHD)

• Coverage may NOT be renewed

#### Hematopoietic Cell Transplantation

• Coverage may NOT be renewed

#### Management of Immunotherapy-Related Toxicities

- Coverage for use in the treatment of myositis/myasthenia gravis/encephalitis may NOT be renewed
- Coverage for use in bullous dermatitis: Patient has not exceeded a maximum of 18 months of therapy (4 total doses)

#### All Other Oncology Indications

• Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread



#### Non-Oncology Indications 1-4

#### Rheumatoid Arthritis (RA)

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as the number of tender and swollen joint counts, reduction of C-reactive protein, improvement of patient global assessment, and/or an improvement on a disease activity scoring tool [e.g. an improvement on a composite scoring index such as Disease Activity Score-28 (DAS28) of 1.2 points or more or a ≥20% improvement on the American College of Rheumatology-20 (ACR20) criteria]; AND
- Dose escalation (up to the maximum dose and frequency specified below) may occur upon clinical review on a case by case basis provided that the patient has:
  - Shown an initial response to therapy; AND
  - Received a minimum of one maintenance dose at the dose <u>and</u> interval specified below; AND
  - Responded to therapy with subsequent loss of response

#### Thrombocytopenic Purpura (ITP or Evans Syndrome) 7-9

• Disease response as indicated by the achievement and maintenance of a platelet count of at least  $50 \times 10^{9}$ /L as necessary to reduce the risk for bleeding

#### Thrombotic Thrombocytopenic Purpura (TTP)

• Disease response as indicated by an increase in ADAMTS13 activity with a reduction in thrombotic risk

#### Multiple Sclerosis (MS) 147,151

• Continuous monitoring of response to therapy indicates a beneficial response\* [manifestations of MS disease activity include, but are not limited to, an increase in annualized relapse rate (ARR), development of new/worsening T2 hyperintensities or enhancing lesions on brain/spinal MRI, and progression of sustained impairment as evidenced by expanded disability status scale (EDSS), timed 25-foot walk (T25-FW), 9-hole peg test (9-HPT)]

#### \*<u>Note</u>:

- Inadequate response, in those who have been adherent and receiving therapy for sufficient time to realize the full treatment effect, is defined as  $\geq 1$  relapse,  $\geq 2$  unequivocally new MRI-detected lesions, or increased disability on examination over a one-year period.

# Granulomatosis with Polyangiitis (GPA) (Wegener's granulomatosis) and Microscopic Polyangiitis (MPA)

• Disease response as indicated by disease control and improvement in signs and symptoms of condition compared to baseline; **AND** 



• Decreased frequency in the occurrence of major relapses (defined by the reappearance of clinical and/or laboratory signs of vasculitis activity that could lead to organ failure or damage, or could be life threatening)

#### Pemphigus Vulgaris <sup>10,11,35,61</sup>

- Patient is currently receiving tapering doses of corticosteroids or has discontinued use of corticosteroids; **AND** 
  - Disease response as indicated by one of the following:
    - Complete epithelialization of lesions and improvement in signs and symptoms of condition compared to baseline
    - Patient has not developed new lesions and established lesions begin to heal
    - For Relapses ONLY: Patient previously achieved disease control; **AND** 
      - Patient has the appearance of 3 or more new lesions a month that do not heal spontaneously within 1 week, or by the extension of established lesions

#### Autoimmune Hemolytic Anemia (AIHA) 31,152

- Disease response as indicated by improvement in signs and symptoms of anemia (e.g., dyspnea, fatigue, etc.); **AND**
- Patient has had an improvement in laboratory values (e.g., hemoglobin, hematocrit, etc.), reduced transfusion needs, and/or reduced glucocorticoid use

# Systemic Lupus Erythematosus (SLE) <sup>153,155,158,161-163</sup>

- Adequate documentation of disease stability and/or improvement as indicated by one or more of the following when compared to pre-treatment baseline:
  - Improvement in the SELENA-SLEDAI-2K; OR
  - Reduction of baseline BILAG-2004 from A to B or from B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥2 new BILAG-2004 B; OR
  - No worsening (<0.30 points increase) in Physician's Global Assessment (PGA) score;</li>
     OR
  - Seroconverted (negative)

#### Lupus Nephritis <sup>115-117</sup>

• Coverage may only be renewed in patients experiencing a disease relapse (e.g., increased serum creatinine, increase in protein urine excretion, decrease in eGFR, etc.)

#### Myasthenia Gravis (unrelated to immunotherapy-related toxicity) <sup>118-120</sup>

• Disease response as indicated by a decrease in the daily dose of corticosteroids and/or an improvement in signs and symptoms compared to baseline.

#### Complications of Transplanted Solid Organ (kidney, liver, lung, heart, pancreas) 133-138



• Coverage may NOT be renewed.

# NMOSD 90,91

- Disease response as indicated by stabilization/improvement in any of the following:
  - o Decrease in acute relapses or improvement of stability
  - Reduced hospitalizations
  - Reduction/discontinuation in plasma exchange treatments
  - $\circ$  Reduction/discontinuation of corticosteroids without relapse

# Antisynthetase Syndrome-Related Interstitial Lung Disease 167,168,174

- Disease response as indicated by stabilization/improvement in any of the following:
  - $\circ$  Reduction or stabilization of glucocorticoid use from baseline
  - Improvement or stabilization of pulmonary function testing (i.e., improvement defined as ≥10% increase in FVC%, TLC%, or DLCO%; stabilization defined as < 10% decrease in FVC%, TLC%, or DLCO%)</li>
  - Improvement or stabilization of chest CT score (i.e., improvement defined as  $\geq 10\%$  decrease in CT score; stabilization defined as a  $\leq 10\%$  increase in CT score)

# Idiopathic Membranous Nephropathy 172,175,177

- Patient experienced beneficial disease response with improvement in symptoms and/or other objective measures compared to baseline (e.g., reduction in proteinuria, increase and/or normalization of serum albumin, improvement/stability of serum creatinine and/or eGFR, decrease in anti-PLA2R antibody levels, etc.); **OR**
- Patient has resistant disease following first-line therapy with rituximab; AND
  - Patient has stable eGFR; AND
  - Will be used in combination with a calcineurin inhibitor if previously treated with rituximab alone in the first-line setting

# Pediatric Idiopathic Nephrotic Syndrome ‡ 170-173

- Patient previously achieved beneficial disease response from the prior course of therapy; **AND**
- Patient is experiencing signs and symptoms of recurrent active disease necessitating additional doses (e.g., recurrence of nephrotic-range proteinuria with a dipstick ≥ 3+ [≥300 mg/dL] for 3 consecutive days <u>OR</u> urinary protein creatinine ratio [UPCR] ≥200 mg/mmol [≥2 mg/mg] on a spot urine sample on 3 consecutive days, with or without reappearance of edema in a child who had previously achieved complete remission)

# IgG4-Related Disease <sup>‡ 178-182</sup>

• Patient experienced beneficial disease response with improvement in involved organ-related symptoms and/or other objective measures compared to baseline (e.g. improvement in the



IgG4-RD Responder Index score of > 2 points, improvement in the physician's global assessment [PGA], reduction in glucocorticoid or other immunosuppressive use, reduction of disease flares, reduction in serum IgG4 level, etc.); **AND** 

- Patient meets one of the following:
  - $\circ$   $\,$  Ongoing maintenance therapy is required due to patient having a high-risk of relapse
  - Patient is experiencing signs and symptoms of relapsed active disease necessitating an additional course of therapy

#### V. Dosage/Administration 1-5,9,19,23-26,32,34,40,42,44,50,62,80,83-89,91,94-98,102-111,115-118,122-125,128-133,135-137,140,152,164,165,167,168, 170-173,175,178-184

Indication		Dose
CLL/SLL	Initial Therapy	375 mg/m <sup>2</sup> intravenously (IV) weekly for 8 doses; <b>OR</b> 375 mg/m <sup>2</sup> IV cycle 1, then 500 mg/m <sup>2</sup> every 28 days cycles 2-6 (6 total doses); <b>OR</b> 375 mg/m <sup>2</sup> IV cycle 1, followed by 500 mg/m <sup>2</sup> every 2 weeks for 4 doses, then 500 mg/m <sup>2</sup> every 28 days for 3 doses (8 total doses)
	Renewal Therapy	375 mg/m² IV every 3 months; <b>OR</b> 500 mg/ m² IV every 8 weeks
Adult B·Cell Lymphomas	Initial Therapy	375 mg/m <sup>2</sup> IV once weekly for 4 - 8 doses in a 6 month period
Castleman Disease, Waldenström Macroglobulinemia, or Adult HL	Renewal Therapy	375 mg/m² IV once weekly for 4 doses per 6 month period; <b>OR</b> 375 mg/ m² IV every 8 weeks
Pediatric Aggressive	Mature B-Cell	Induction* [courses 1 and 2 (COPDAM1 and COPDAM2)]
Lymphomas		375 mg/m <sup>2</sup> IV, two doses during each of the induction courses (Day -2 and Day 1).
		During the 1 <sup>st</sup> induction course, prednisone is given as part of the chemotherapy course, and should be administered prior to rituximab. Rituximab will be given 48 hours after the first infusion of rituximab.
		Consolidation* [courses 1 and 2 (CYM/CYVE)]
		375 mg/m² IV, one dose during each of the consolidation courses (Day 1)
		Relapsed/Refractory
		RCYVE – 375mg/m² IV on day 1 of each 21-day cycle
		RICE – 375 mg/m² IV on days 1 and 3 of courses 1 and 2, and on day 1 only of course 3 if needed.
		*Note: dosing and dosing schedules are highly variable and dependent on regimen used, please refer to NCCN and PI for additional protocols.
Pediatric Mature B-Cell Acute Leukemia		Induction* [courses 1 and 2 (COPDAM1 and COPDAM2)]

RITUXIMAB -E- (Rituxan<sup>®</sup>, Truxima<sup>®</sup>, Ruxience<sup>®</sup>, Riabni<sup>™</sup>)
 Prior Auth Criteria
 Proprietary Information. Restricted Access – Do not disseminate or copy without approval.
 ©2024, Magellan Rx Management



T

Indication	Dose
	375 mg/m <sup>2</sup> IV, two doses during each of the induction courses (Day -2 and Day 1).
	During the 1 <sup>st</sup> induction course, prednisone is given as part of the chemotherapy course, and should be administered prior to rituximab. Rituximab will be given 48 hours after the first infusion of rituximab.
	Consolidation* [courses 1 and 2 (CYM/CYVE)]
	375 mg/m <sup>2</sup> IV, one dose during each of the consolidation courses (Day 1)
	*Note: dosing and dosing schedules are highly variable and dependent on regimen used, please refer to NCCN and PI for additional protocols.
CNS Lymphoma	Intravenous administration
	<u>Initial Therapy</u> : 375 mg/m <sup>2</sup> IV once weekly for 4 - 8 doses in a 6 month period
	<u>Renewal Therapy:</u> 375 mg/m <sup>2</sup> IV once weekly for 4 doses per 6 month period; <b>OR</b>
	375 mg/ m² IV every 8 weeks
	Intrathecal/Intraventricular administration
	10-40 mg weekly to every 3 weeks
ALL	375 mg/m <sup>2</sup> IV up to twice weekly for a total of 16 to 18 infusions (e.g., induction [days 1 and 7], salvage reinduction when necessary [days 1 and 7], consolidation [4 infusions: blocks 1, 3, 4, and 6], late intensification [days 1 and 7], late consolidation [2 infusions: blocks 7 and 9], and maintenance [6 infusions])
Hairy Cell Leukemia	$375 \text{ mg/m}^2$ IV once weekly for $4 - 8$ doses; <b>OR</b>
	375mg/m <sup>2</sup> IV on days 1 and 15 every 28 days for 4 cycles, then 375mg/m <sup>2</sup> IV every 4 weeks for 4 cycles (up to 8 <u>total</u> cycles)
RA	1,000 mg IV on days 1 and 15, repeated every 24 weeks. May repeat up to every 16 weeks following the previous infusion in patients requiring more frequent dosing based on clinical evaluation.
	Initiation
	1,000 IV mg on days 1 and 15; <b>OR</b>
	375 mg/m <sup>2</sup> IV weekly for 4 doses
	Maintenance
Pemphigus Vulgaris	500 mg IV at month 12 and repeat every 6 months thereafter or based on clinical evaluation.
	Relapse
	1,000 IV mg upon relapse, resumption of glucocorticoids may be considered.
	*Subsequent infusions (maintenance and relapse) should be no sooner than 16 weeks after the previous infusion.

RITUXIMAB -E- (Rituxan<sup>®</sup>, Truxima<sup>®</sup>, Ruxience<sup>®</sup>, Riabni<sup>™</sup>) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval. ©2024, Magellan Rx Management



Indication	Dose
AIHA	<u>Warm-reactive disease</u> 375 mg/m² IV weekly for 4 doses in a 6 month period; <b>OR</b> 1,000 mg IV on days 1 and 15
	<u>Cold agglutinin disease</u> 375 mg/m² IV weekly for 4 doses in a 6 month period
Thrombocytopenic Purpura or Thrombotic Thrombocytopenic Purpura (TTP)	375 mg/m² IV weekly for 4 doses; <b>OR</b> 1,000 mg IV on days 1 and 15
Management of Immunotherapy- Related Toxicities	Bullous Dermatitis1,000 mg IV every 2 weeks for 2 doses, then 500 mg IV at months12 and 18 as neededMyositis375 mg/m² IV weekly for 4 doses
	<u>Myasthenia Gravis</u> 375 mg/m² IV weekly for 4 doses; <b>OR</b> 500 mg/m² IV every 2 weeks for 2 doses <u>Encephalitis</u> 1.000 mg IV every 2 weeks for 2 doses; <b>OR</b>
	375 mg/m <sup>2</sup> IV weekly for 4 doses
GPA (WG), MPA	<ul> <li>Induction (Pediatric and Adult)</li> <li>375 mg/m<sup>2</sup> IV weekly for 4 doses; OR</li> <li>Adults: 1,000 mg IV on days 1 and 15; OR</li> <li>Pediatric (up to a maximum of 1,000 mg per dose): <ul> <li>575 mg/m<sup>2</sup> IV on days 1 and 15 (BSA ≤1.5m<sup>2</sup>)</li> <li>750 mg/m<sup>2</sup> IV on days 1 and 15 (BSA &gt;1.5m<sup>2</sup>)</li> </ul> </li> </ul>
	<ul> <li><u>Maintenance</u></li> <li>Pediatric: <ul> <li>250 mg/m<sup>2</sup> IV on days 1 and 15, then 250 mg/m<sup>2</sup> IV every 6 months thereafter based on clinical evaluation</li> </ul> </li> <li>Adult: <ul> <li>500 mg to 1,000 mg IV on days 1 and 15, then 500 mg to 1,000 mg IV every 6 months thereafter based on clinical</li> </ul> </li> </ul>
	evaluation. *Initial MAINTENANCE infusions should be no sooner than 16 weeks and no later than 24 weeks after the previous infusion if rituximab was used for initial induction therapy. *Initial MAINTENANCE infusions should be initiated within 4 weeks following disease control when initial induction occurred with other standard of care immunosuppressants.



Indication	Dose
cGVHD	375 mg/m <sup>2</sup> IV weekly for 4 doses, then 375 mg/m <sup>2</sup> IV monthly for 4 months - <b>OR</b> -
	375 mg/m <sup>2</sup> IV weekly for 4 doses ( <i>Note: A second course of 4 weekly doses may be administered 8 weeks after initial therapy for patients with lack of or incomplete response.</i> ) - <b>OR</b> -
	375 mg/m² IV weekly for 4 - 8 doses
Hematopoietic Cell Transplantation	<u>Conditioning</u> : 375 mg/m² IV for 1 day before transplant, then 1000 mg/m² IV on days 1,8, and 15 after transplant
Multiple Sclerosis	1,000 mg IV on days 1 and 15, repeat every 6 months
NMOSD	1,000 mg IV once on days 1 and 15, repeat every 6 months -OR-
	375 mg/m <sup>2</sup> once weekly for 4 weeks, repeat every 6 months
SLE	1,000 mg IV on days 1 and 15
	375 mg/m² IV once weekly for 4 doses
Lupus Nephritis	1,000 mg IV on days 1 and 15 - <b>OR-</b>
	375 mg/m² IV once weekly for 4 doses
Myasthenia Gravis (unrelated to immunotherapy-related toxicity)	1,000 mg IV on days 1 and 15, may repeat a full or partial course every 6 months -OR-
	375 mg/m <sup>2</sup> IV once weekly for 4 doses, may repeat a full or partial course every 6 months
Complications of transplanted solid organ (kidney, liver, lung, heart, pancreas)	<ul> <li>Adults and pediatrics weighing ≥0.5 m<sup>2</sup>: 375 mg/m<sup>2</sup> weekly for up to 4 doses</li> <li>Pediatrics weighing &lt;0.5 m<sup>2</sup>: 12.5 mg/kg weekly for up to 4 doses</li> </ul>
Antisynthetase Syndrome-Related Interstitial Lung Disease	1,000 mg IV on days 1 and 15 repeated every 6 months -OR-
	375 mg/m² IV once weekly for 4 doses repeated every 6 months
Pediatric Idiopathic Nephrotic Syndrome	375 mg/m² IV once weekly for 1-4 doses
Idiopathic Membranous Nephropathy	375 mg/m² IV once weekly for 1-4 doses every 6 months -OR-
	1,000 mg IV on days 1 and 15 every 6 months
IgG4-Related Disease	Induction:

RITUXIMAB -E- (Rituxan<sup>®</sup>, Truxima<sup>®</sup>, Ruxience<sup>®</sup>, Riabni<sup>™</sup>) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval. ©2024, Magellan Rx Management



Indication	Dose
	375 mg/m² IV once weekly for 1-4 doses
	-OR-
	1,000 mg IV on days 1 and 15
	*Subsequent infusions (maintenance and relapse) may be administered at either induction schedule above and should be repeated no sooner than every 6 months.
All  :  :  :  :  :  :  :  :  :	$(\cdot, \cdot, \cdot, \cdot) = 1 + \cdots + (OOPDAM - O + 1 + 1 + 1 + 0) + (\cdot, \cdot, \cdot)$

<u>Abbreviations</u>: COP = Cyclophosphamide, Oncovin (vincristine), Prednisone; COPDAM = Cyclophosphamide, Oncovin (vincristine), Prednisolone, Adriamycin (doxorubicin), Methotrexate; CYM = Cytarabine (Ara-C), Methotrexate; CYVE = Cytarabine (Ara-C), Vepesid (Etoposide, VP-16); RICE = Rituximab, Ifosfamide, Carboplatin, Etoposide (VP-16)

#### VI. Billing Code/Availability Information

#### HCPCS Code(s):

- J9312 Injection, rituximab, 10 mg; 1 billable unit = 10 mg (*Rituxan IV only*)
- Q5115 Injection, rituximab-abbs, biosimilar, (truxima), 10 mg; 1 billable unit = 10 mg
- Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg; 1 billable unit = 10 mg
- Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg; 1 billable unit = 10 mg

#### NDC(s):

- Rituxan 100 mg/10 mL single-dose vial for injection: 50242-0051-xx
- Rituxan 500 mg/50 mL single-dose vial for injection: 50242-0053-xx
- Truxima 100 mg/10 mL single-dose vial for injection: 63459-0103-xx
- Truxima 500 mg/50 mL single-dose vial for injection: 63459-0104-xx
- Ruxience 100 mg/10 mL single-dose vial for injection: 00069-0238-xx
- Ruxience 500 mg/50 mL single-dose vial for injection: 00069-0249-xx
- Riabni 100 mg/10 mL single-dose vial for injection: 55513-0224-xx
- Riabni 500 mg/50 mL single-dose vial for injection: 55513-0326-xx

# VII. References (STANDARD)

- 1. Rituxan [package insert]. South San Francisco, CA; Genentech, Inc; December 2021. Accessed April 2024.
- 2. Truxima [package insert]. Incheon, Republic of Korea; Celltrion, Inc; November 2023. Accessed April 2024.
- 3. Ruxience [package insert]. New York, NY; Pfizer, Inc; October 2023. Accessed April 2024.
- 4. Riabni [package insert]. Thousand Oaks, CA; Amgen, Inc; February 2023. Accessed April 2024.
- 5. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) rituximab. National Comprehensive Cancer Network, 2024. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most



recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2024.

- Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146:25-33.
- 7. Zaja F, Baccarani M, Mazza P, et al: Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010; 115(14):2755-2762.
- Stasi R, Pagano A, Stipa E, et al: Rituximab chimeric anti-CD10 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98(4):952-957.
- 9. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 117(16):4190-4207.
- 10. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357:545-52.
- 11. Ahmed AR, Spigelman Z, Cavacini LA et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355:1772-9.
- 12. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2015 Nov 6. doi: 10.1002/acr.22783.
- 13. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Mar 6. pii: annrheumdis-2016-210715.
- 14. González-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica. 2007 Nov; 92(11):1489-94.
- 15. Chamberlain MC, Johnston SK, Van Horn A, et al. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol. 2009 Feb;91(3):271-7.
- 16. Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007;136:451-461.
- 17. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005;106:1932-37.
- 18. Elliott MA, Heit JA, Rajiv K, et al. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol 2009. Epub ahead of print, doi:10.1111/j.1600-0609.2009.01292.



- Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746-1753.
- 20. Tun NM, Villani GM. Efficacy of rituximab in acute refractory or chronic relapsing nonfamilial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis. J Thromb Thrombolysis. 2012;34(3):347-359.
- 21. Froissart A, Buffet M, Veyradier A, et al: Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012; 40(1):104-111.
- 22. van Dorp S, Resemann H, te Boome L, et al. The immunological phenotype of rituximabsensitive chronic graft-versus-host disease: a phase II study. Haematologica 2011;96(9):1380-1384.
- 23. Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica 2010;95(11):1935-1942.
- 24. Cutler C, Miklos D, Kim HT, et al. Rituximab for Steroid-Refractory Chronic Graft-Versus-Host Disease. Blood. 2006, 108(2):756-62.
- 25. Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2011 Jan;17(1):1-17. doi: 10.1016/j.bbmt.2010.05.011.
- 26. Frame JN, Fichtner R, McDevitt PW. Rituximab for the treatment of autoimmune hemolytic anemia (AIHA) in adults: an analysis of literature reports in 92 patients. Blood 2004;104:Abstract 3721.
- 27. Birgens H, Frederiksen H, Hasselbalch HC, et al: A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol 2013; 163(3):393-399.
- 28. Schollkopf C, Kjeldsen L, Bjerrum OW, et al: Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 2006; 47(N2):253-260.
- 29. Berentsen S, Ulvestad E, Gjertsen BT, et al: Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004; 103(8):2925-2928.
- 30. Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev. 2015;14(4):304-313.
- 31. Barcellini W, Zaja F, Zaninoni A, et al, "Low-dose Rituximab in Adult Patients With Idiopathic Autoimmune Hemolytic Anemia: Clinical Efficacy and Biologic Studies," Blood, 2012, 119(16):3691-7.
- 32. Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. Am J Hematol. 2014;89(9):E150-E155.



- 33. Gobert D, Bussel JB, Cunningham-Rundles C, et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol. 2011;155(4):498-508.
- 34. YW Shin, ST Lee, KI Park, et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. 2017 Aug 16;11:1756285617722347. doi: 10.1177/1756285617722347. eCollection 2018. Review.
- 35. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008 June; 58(6): 1043–1046. doi:10.1016/j.jaad.2008.01.012. Avail at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829665/pdf/nihms82304.pdf
- 36. Grover, S. Scoring Systems in Pemphigus. Indian J Dermatol. 2011 Mar-Apr; 56(2): 145–149. doi: 10.4103/0019-5154.80403
- 37. Daniel BS, Hertl M, Weth VP, et al. Severity score indexes for blistering diseases. Clin Dermatol. 2012 Jan-Feb; 30(1): 108–113. doi: 10.1016/j.clindermatol.2011.03.017
- 38. Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol 2011; 29:432.
- 39. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017. 129:2829-2835. doi:10.1182/blood-2017-03-754119
- 40. Schulz H, Pels H, Schmidt-Wolf I, et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica January 2004 89: 753-754
- 41. Fahrenbruch R, Kintzel P, Bott AM, et al. Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association. J Oncol Pract. 2018 Mar;14(3):e130-e136.
- 42. Hematology/Oncology Pharmacy Association (2019). *Intravenous Cancer Drug Waste Issue Brief.* Retrieved from http://www.hoparx.org/images/hopa/advocacy/Issue-Briefs/Drug\_Waste\_2019.pdf
- 43. Bach PB, Conti RM, Muller RJ, et al. Overspending driven by oversized single dose vials of cancer drugs. BMJ. 2016 Feb 29;352:i788.
- 44. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas, Version 1.2024. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed April 2024.
- 45. Imbruvica [package insert]. Horsham, PA; Janssen Biotech, Inc. May 2023. Accessed February 2024.
- 46. Keystone E, Burmester GR, Furie R, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2008 Jun 15;59(6):785-93. doi: 10.1002/art.23715.



- 47. Mease PJ, Cohen S, Gaylis NB, et al. Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial. The Journal of Rheumatology May 2010, 37 (5) 917-927; DOI: https://doi.org/10.3899/jrheum.090442
- 48. Tak PP, Rigby W, Rubbert-Roth A, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012 Mar;71(3):351-7. doi: 10.1136/annrheumdis-2011-200170. Epub 2011 Oct 19.
- 49. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010 Sep;69(9):1629-35. doi: 10.1136/ard.2009.119933. Epub 2010 May 20. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.
- 50. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Aggressive Mature B-Cell Lymphomas, Version 1.2024. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed April 2024.
- 51. Lee KH, Lee J, Bae JS, et al. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product. MAbs. 2018;10(3):380-396
- 52. Ogura M, Sancho JM, Cho S-G, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumourburden follicular lymphoma: a randomised, double-blind, parallel-group phase 3 trial. Lancet Haematol. 2018;5:e543-e553.
- 53. Gulácsi L, Brodszky V, Baji P, et al. The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. Adv Ther. 2017; 34: 1128-1144.
- 54. Yoo DH, Suh CH, Shim SC, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017; 76: 566-570.
- 55. Suh C, Berrocal Kasay A, Chalouhi El-Khouri E, et al. Pharmacokinetics and safety of three formulations of rituximab (CT-P10, US-sourced innovator rituximab and EU-sourced innovator rituximab) in patients with rheumatoid arthritis: results from phase 3 randomized controlled trial over 24 weeks. Arthritis Rheumatol. 2016; 68: 1634.
- 56. Kim WS, Buske C, Ogura M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol. 2017; 4: e362-e373.
- 57. Cohen S, Emery P, Greenwald M, et al. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. Br J Clin Pharmacol. 2016 Jul;82(1):129-38.



- 58. Williams JH, Hutmacher MM, Zierhut ML, et al. Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab. Br J Clin Pharmacol. 2016 Dec;82(6):1568-1579.
- 59. Sharman JP, Liberati AM, Ishizawa K, et al. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL). BioDrugs. 2019 Dec 9. doi: 10.1007/s40259-019-00398-7.
- 60. Cohen SB, Burgos-Vargas R, Emery P, et al. Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab. Br J Clin Pharmacol. 2016 Dec;82(6):1568-1579.
- 61. Murrel DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. JAAD: Mar2020;82;3;575-585. DOI:https://doi.org/10.1016/j.jaad.2018.02.021.
- 62. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Management of Immunotherapy-Related Toxicities, Version 1.2024. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed April 2024.
- Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia [published correction appears in Blood Adv. 2020 Jan 28;4(2):252]. Blood Adv. 2019;3(23):3829-3866. Doi:10.1182/bloodadvances.2019000966.
- 64. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33.
- 65. Piro LD, White CA, Grillo-López AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999;10(6):655-661. Doi:10.1023/a:1008389119525.
- 66. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18(17):3135-3143. Doi:10.1200/JCO.2000.18.17.3135.
- 67. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417-1423. Doi:10.1182/blood-2004-08-3175.
- 68. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial [published correction appears in Lancet. 2011 Apr 2;377.
- 69. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent



lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009;27(10):1607-1614. Doi:10.1200/JCO.2008.17.1561.

- 70. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-3127. Doi:10.1200/JCO.2005.05.1003,
- 71. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040-2045. Doi:10.1182/blood-2010-03-276246.
- 72. Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MinT) Group. Lancet Oncol. 2011;12(11):1013-1022. Doi:10.1016/S1470-2045(11)70235-2.
- 73. Dakhil S, Hermann R, Schreeder MT, et al. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. Leuk Lymphoma. 2014;55(10):2335-2340. Doi:10.3109/10428194.2013.877135.
- 74. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208-215. Doi:10.1182/blood-2015-06-651125.
- 75. Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 1;28(10):1756-65.
- 76. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. Doi:10.1056/NEJMoa0909905.
- 77. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771-1780. Doi:10.1056/NEJMoa1404231.
- 78. Niles JL, Merkel PA, Mertz L, et al. Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Results of the Four-Year Study of Rituximab in ANCA-Associated Vasculitis Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).
- 79. Brogan P, Cleary G, Hersh AO, et al. Pediatric Open-Label Clinical Study of Rituximab for the Treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).
- 80. Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-2040. Doi:10.1016/S0140-6736(17)30070-3.



- 81. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880-3889. Doi:10.1200/JCO.2009.26.9456.
- 82. Kadia TM, Kantarjian HM, Thomas DA, et al. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MopAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015;90(2):120-124. Doi:10.1002/ajh.23886.
- 83. Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 2013;27(5):1174-1177. doi:10.1038/leu.2012.255.
- 84. Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;52(2):177-181. doi:10.1002/pbc.21753.
- 85. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell posttransplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107(8):3053-3057. doi:10.1182/blood-2005-01-0377.
- 86. Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13(2):196-206.
- 87. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28(8):1422-1428. doi:10.1200/JCO.2009.25.3237.
- 88. Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2014;32(9):912-918. doi:10.1200/JCO.2013.53.2069.
- 89. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999-1004. doi:10.1182/blood-2008-01-131029.
- Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul;85(2):177-89. Epub 2015 Jun 19.
- 91. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261:1.
- 92. Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264(9):2003. Epub 2017 Aug 22.



- 93. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia, Version 4.2023. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed April 2024.
- 94. Thomas DA, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003 Dec 1;102(12):3906-11. doi: 10.1182/blood-2003-02-0630.
- 95. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003 Aug 1;102(3):810-3.
- 96. Chihara D, Kantarjian H, O'Brien S, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016 Sep;174(5):760-6.
- 97. Else M, Dearden CE, Matutes E, et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma. 2011 Jun;52 Suppl 2:75-8. doi: 10.3109/10428194.2011.568650.
- 98. Zenhäusern R, Simcock M, Gratwohl A, et al; Swiss Group for Clinical Cancer Research (SAKK). Rituximab in patients with hairy cell leukemia relapsing after treatment with 2chlorodeoxyadenosine (SAKK 31/98). Haematologica. 2008 Sep;93(9):1426-8.
- 99. Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013 Nov;163(3):393-9. doi: 10.1111/bjh.12541.
- 100. Niederwieser, D., Hamm, C., Cobb, P. et al. Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product. Targ Oncol 15, 599–611 (2020). https://doi.org/10.1007/s11523-020-00748-4.
- 101. Burmester, G., Drescher, E., Hrycaj, P. et al. Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis. Clin Rheumatol 39, 3341–3352 (2020). https://doi.org/10.1007/s10067-020-05305-y.
- 102. Solimando AG, Crudele L, Leone P, et al. Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside. Int J Mol Sci. 2020;21(9):3054. Published 2020 Apr 26. doi:10.3390/ijms21093054.
- 103. Kong SS, Chen YJ, Su IC, et al; CHEESE Study Group. Immunotherapy for anti-NMDA receptor encephalitis: Experience from a single center in Taiwan. Pediatr Neonatol. 2019 Aug;60(4):417-422. doi: 10.1016/j.pedneo.2018.10.006.
- 104. Feng S, Coward J, McCaffrey E, et al. Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors. J Thorac Oncol. 2017 Nov;12(11):1626-1635. doi: 10.1016/j.jtho.2017.08.007.



- 105. Chamberlain MC, Johnston SK, Van Horn A, et al. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol. 2009 Feb;91(3):271-7. doi: 10.1007/s11060-008-9707-1. Epub 2008 Sep 27.
- 106. Rituximab in the treatment of Rosai-Dorfman syndrome with IgG4 disease. Journal of the American Academy of Dermatology 2019; 81: AB269.
- 107. Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood (2018) 131 (26): 2877–2890.
- 108. Maury S, Chevret S, Thomas X, et al; for GRAALL. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Sep 15;375(11):1044-53. doi: 10.1056/NEJMoa1605085.
- 109. Wieduwilt MJ, Jonas BA, Schiller GJ, et al; A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401. Blood 2018; 132 (Supplement 1): 4018. doi: https://doi.org/10.1182/blood-2018-99-117469.
- 110. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer, 106: 1569-1580. https://doi.org/10.1002/cncr.21776.
- 111. Kreitman RJ, Wilson W, Calvo KR, et al. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res. 2013 Dec 15;19(24):6873-81. doi: 10.1158/1078-0432.CCR-13-1752.
- 112. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021 Jul;73(7):1108-1123. doi: 10.1002/art.41752.
- 113. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases 2020;79:685-699.
- 114. Venugopal SS, Murrell DF. Diagnosis and clinical features of pemphigus vulgaris. Dermatol Clin. 2011 Jul;29(3):373-80, vii. doi: 10.1016/j.det.2011.03.004. PMID: 21605802.
- 115. Fanouriakis A, Kostopoulou M, Cheema K, et al: 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020; 79(6):713-723.
- 116. Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8(3):R83. doi: 10.1186/ar1954. Epub 2006 May 5.



- 117. Melander C, Sallée M, Trolliet P, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 2009 Mar;4(3):579-87. doi: 10.2215/CJN.04030808. Epub 2009 Mar 4.
- 118. Bird SJ. (2024). Chronic immunosuppressive therapy for myasthenia gravis. In Shefner JM, Goddeau RP (Eds.), *UptoDate*. Last updated: February 27, 2024. Accessed: April 2024. Available from <u>https://www.uptodate.com/contents/chronic-immunotherapy-for-myastheniagravis.</u>
- 119. Topakian R, Zimprich F, Iglseder S, et al. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J Neurol. 2019;266(3):699-706. doi:10.1007/s00415-019-09191-6.
- 120.Li T, Zhang GQ, Li Y, et al. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: a meta-analysis. J Clin Neurosci. 2021;85:6-12. Doi:10.1016/j.jocn.2020.11.043.
- 121. Colin V, Auperin A, Pillon M, et al. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. Clinical Trial. N Engl J Med. 2020 Jun 4;382(23):2207-2219. doi: 10.1056/NEJMoa1915315.
- 122. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997-1007. doi:10.1056/NEJMoa1315226.
- 123. Greil R, Obrtlíková P, Smolej L, et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol. 2016 Jul;3(7):e317-29. doi: 10.1016/S2352-3026(16)30045-X.
- 124. Dartigeas C, Van Den Neste E, Léger J,et al. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematol. 2018 Feb;5(2):e82-e94. doi: 10.1016/S2352-3026(17)30235-1.
- 125. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken). 2021;73(8):1088. Epub 2021 Jul 8.
- 126. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2496-2502. doi:10.1111/jth.15010.
- 127. Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009 Oct 8;114(15):3167-72. doi: 10.1182/blood-2009-04-215368.
- 128. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Hodgkin Lymphoma, Version 2.2023. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER



NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed April 2024.

- 129. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation, Version 3.2023. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed April 2024.
- 130. Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15;98(13):3595-9. doi: 10.1182/blood.v98.13.3595.
- 131. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, et al. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and metaanalysis. Biol Blood Marrow Transplant. 2009 Sep;15(9):1005-13. doi: 10.1016/j.bbmt.2009.04.003.
- 132. Rovin BH, Furie R, Latinis K, et al; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359.
- 133. McDonald RA. (2023). Kidney transplantation in children: Immunosuppression. In Niaudet P, Hoppin AG (Eds.), *UptoDate*. Last updated: Dec 14, 2023. Accessed: April 2024. Available from <a href="https://www.uptodate.com/contents/kidney-transplantation-in-children-immunosuppression?search=pediatric%20antibody%20mediated%20rejection&source=search\_result&selectedTitle=1~150&usage\_type=default&display\_rank=1#H181637276.</a>
- 134. Parajuli S, Brennan DC. (2022). Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection. In Legendre C, Vella J, Lam AQ (Eds.), UptoDate. Last updated: September 16, 2022. Accessed: April 2024. Available from <u>https://www.uptodate.com/contents/kidney-transplantation-in-adults-prevention-andtreatment-of-antibody-mediatedrejection?search=Antibody%20mediated%20rejection&source=search\_result&selectedTitle=1 ~150&usage\_type=default&display\_rank=1.</u>
- 135. Colvin MM, Cook JL, Chang P, et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2015 May 5;131(18):1608-39. doi: 10.1161/CIR.000000000000093.
- 136. Hachem RR. (2023). Evaluation and treatment of antibody-mediated lung transplant rejection. In Kotloff RM, Dieffenbach P (Eds.), *UptoDate*. Last updated: Feb 3, 2023. Accessed: April 2024. Available from <u>https://www.uptodate.com/contents/evaluation-and-treatment-of-antibody-mediated-lung-transplant-rejection.</u>

RITUXIMAB -E- (Rituxan<sup>®</sup>, Truxima<sup>®</sup>, Ruxience<sup>®</sup>, Riabni<sup>™</sup>)
 Prior Auth Criteria
 Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2024, Magellan Rx Management

Page 33



- 137.Alhamad T, Kukla A, Stratta RJ. (2022). Pancreas allograft rejection. In Brennan DC, Nathan DM, Lam AQ (Eds.), *UptoDate*. Last updated: December 7, 2022. Accessed: April 2024. Available from <u>https://www.uptodate.com/contents/pancreas-allograft-rejection</u>.
- 138. Sakamoto S, Akamatsu N, Hasegawa K, et al. The efficacy of rituximab treatment for antibody-mediated rejection in liver transplantation: A retrospective Japanese nationwide study. Hepatol Res. 2021 Sep;51(9):990-999. doi: 10.1111/hepr.13643.
- 139.Joly P, Horvath B, Patsatsi A, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV). Journal of the European Academy of Dermatology & Venereology. 2020 Sept; 34(9):1900-1913.
- 140. Senff NJ, Noordijk EM, Kim YH, et al.; European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008 Sep 1;112(5):1600-9. Doi: 10.1182/blood-2008-04-152850. Epub 2008 Jun 20. PMID: 18567836.
- 141. Gawronski KM, Rainka MM, Patel MJ, Gengo FM. Treatment Options for Multiple Sclerosis: Current and Emerging Therapies. Pharmacotherapy. 2010; 30(9):916-927.
- 142. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002 Jan 22; 58(2):169-78.
- 143. Freedman MS, Selchen D, Arnold DL, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013 May;40(3):307-23.
- 144. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011 Feb; 69(2): 292–302. doi: 10.1002/ana.22366.
- 145. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014 Jul 15;83(3):278-86.
- 146. Multiple Sclerosis Coalition. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. 2017 March. http://www.nationalmssociety.org/getmedia/5ca284d3-fc7c-4ba5-b005ab537d495c3c/DMT\_Consensus\_MS\_Coalition\_color. Accessed 4/2018.
- 147.Rae-Grant, A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology® 2018;90:777-788.
- 148. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2.



- 149. Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263. Epub 2018 Mar 23.
- 150. Lorscheider J, Buzzard K, Jokubaitis V, et al, on behalf of the MSBase Study Group. Defining secondary progressive multiple sclerosis. Brain, Volume 139, Issue 9, September 2016, Pages 2395–2405, <u>https://doi.org/10.1093/brain/aww173</u>.
- 151. Freedman MS, Devonshire V, Duquette P, et al; Canadian MS Working Group. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci. 2020 Jul;47(4):437-455. doi: 10.1017/cjn.2020.66.
- 152. Miche M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Am J Hematol. 2017;92:23-27. <u>https://doi.org/10.1002/ajh.24570</u>
- 153. Fanouriakis A, Kostopoulou M, Alunno A, et al: 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019; 78(6):736-745.
- 154. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum. 1999;42(9):1785–1796.
- 155. Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018 Jan 1;57(1):e1-e45. doi: 10.1093/rheumatology/kex286.
- 156. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021 Jan 19;96(3):114-122. doi: 10.1212/WNL.000000000011124.
- 157.Jarius, S., Aktas, O., Ayzenberg, I. et al. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol 270, 3341–3368 (2023). <u>https://doi.org/10.1007/s00415-023-11634-0</u>
- 158. Fanouriakis A, Tziolos N, Bertsias G, et al. Update on the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 2021; 80:14-25. doi:10.1136/annrheumdis-2020-218272
- 159. Aringer M, Costenbader K, Daikh D, et al. 2019 European League against Rheumatism/American College of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1400–12.
- 160.Lam NC, Brown JA, Sharma R. Systemic Lupus Erythematosus: Diagnosis and Treatment. Am Fam Physician. 2023 Apr 107(4):383-395.
- 161.Yee CS, Cresswell L, Farewell V, Rahman A, Teh LS, Griffiths B et al. Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford) 2010; 49(9):1665-9.
- 162.Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29(2):288-91.



- 163. Chessa E, Piga M, Floris A, Devilliers H, Cauli A, Arnaud L. Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. Rheumatology (Oxford). 2020 Dec 1;59(12):3622-3632. doi: 10.1093/rheumatology/keaa383.
- 164. Tiacci E, De Carolis L, Santi A, Falini B. Venetoclax in relapsed or refractory hairy-cell leukemia. N Engl J Med 2023;388:952-954.
- 165. Kümpfel T, Giglhuber K, Aktas O, et al. Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)
  revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2023 Sep 7. doi: 10.1007/s00415-023-11910-z. Epub ahead of print.
- 166. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney Int. 2024;105(1S):S1–S69.
- 167. Doyle TJ, Dhillon N, Madan R, et al. Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review. J Rheumatol. 2018 Jun;45(6):841-850. doi: 10.3899/jrheum.170541.
- 168. Anderson H, Sem M, Lund M, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease, Rheumatology, Volume 54, Issue 8, August 2015, Pages 1420–1428. doi.org/10.1093/rheumatology/kev004
- 169. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762.
- 170. Trautmann A, Boyer O, Hodson E, et al. International Pediatric Nephrology Association. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023 Mar;38(3):877-919. doi: 10.1007/s00467-022-05739-3.
- 171. Trautmann A, Vivarelli M, Samuel S, et al. International Pediatric Nephrology Association. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020 Aug;35(8):1529-1561. doi: 10.1007/s00467-020-04519-1.
- 172. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
- 173. Kallash M, Smoyer WE, Mahan JD. Rituximab Use in the Management of Childhood Nephrotic Syndrome. Front Pediatr. 2019 May 10;7:178. doi: 10.3389/fped.2019.00178.
- 174. Sawal N, Mukhopadhyay S, Rayancha S, et al. A narrative review of interstitial lung disease in anti-synthetase syndrome: a clinical approach. J Thorac Dis. 2021 Sep;13(9):5556-5571. doi: 10.21037/jtd-20-3328. PMID: 34659821; PMCID: PMC8482343.



- 175. Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427.
- 176. Beck LH, Salant DJ. (2024). Membranous nephropathy: Pathogenesis and etiology. In Glasscock RJ, Fervenza FC, Lam AQ (Eds.), *UptoDate*. Last updated: March 4, 2024. Accessed: April 2024. Available from <u>https://www.uptodate.com/contents/membranousnephropathy-pathogenesis-and-etiology</u>
- 177. De Vriese AS, Wetzels JFM, Cattran DC. (2024). Membranous nephropathy: Treatment and prognosis. In Glasscock RJ, Fervenza FC, Lam AQ (Eds.), *UptoDate*. Last updated: March 8, 2024. Accessed: April 2024. Available from <u>https://www.uptodate.com/contents/membranousnephropathy-treatment-and-prognosis</u>
- 178. Khosroshahi A, Wallace ZS, Crowe JL, et al. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheumatol. 2015;67(7):1688-1699. doi:10.1002/art.39132
- 179. Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4related disease: Data from a French nationwide study of thirty-three patients. PLoS One. 2017;12(9):e0183844. Published 2017 Sep 15. doi:10.1371/journal.pone.0183844
- 180. Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171-1177.
- 181. Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum. 2010;62(6):1755-1762.
- 182. Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012;91(1):57-66.
- 183.Ly KI, Crew LL, Graham CA, Mrugala MM. Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience. Oncol Lett 2016;11:3471-3476.
- 184. Smith R, Jones R, Guerry M, at al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012 Nov;64(11):3760-9. doi: 10.1002/art.34583.
- 185. National Government Services, Inc. Local Coverage Article: Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars (A59101). Centers for Medicare & Medicaid Services, Inc. Updated on 01/26/2024 with effective date of 02/01/2024. Accessed April 2024.
- 186. Wisconsin Physicians Service Insurance Corp. Local Coverage Article: Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions (A55639). Centers for Medicare & Medicaid Services, Inc. Updated on 11/20/2023 with effective date 11/30/2023. Accessed April 2024.



- 187. Palmetto GBA. Local Coverage Article: Billing and Coding: Rituximab (A56380). Centers for Medicare & Medicaid Services, Inc. Updated on 08/11/2023 with effective date of 10/01/2023. Accessed April 2024.
- 188. CGS Administrators, LLC. Local Coverage Article: Billing and Coding: Immune Thrombocytopenia (ITP) Therapy (A57160). Centers for Medicare & Medicaid Services, Inc. Updated on 02/29/2024 with effective date 03/07/2024. Accessed April 2024.
- 189. CGS Administrators, LLC. Local Coverage Article: Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars (A58582). Centers for Medicare & Medicaid Services, Inc. Updated on 11/15/2023 with effective date 11/22/2023. Accessed April 2024.

# VIII. References (ENHANCED)

- 1e. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Central Nervous System Cancers. Version 1.2023. National Comprehensive Cancer Network, 2024. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2024.
- 2e. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Hodgkin Lymphoma. Version 3.2024. National Comprehensive Cancer Network, 2024. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2024.
- 3e. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 3.2024. National Comprehensive Cancer Network, 2024. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2024.
- 4e. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma. Version 2.2024. National Comprehensive Cancer Network, 2024. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2024.
- 5e. Maury S, Chevret S, Thomas X, et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N Engl J Med 2016; 375:1044-1053.



- 6e. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med 2017; 376:836-847.
- 7e. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25;375(8):740-53.
- 8e. Maude S, Laetsch T, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 2018; 378:439-448.
- 9e. Chamberlain MC, Johnston SK, Van Horn A, Glantz MJ. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol. 2009 Feb;91(3):271-7.
- 10e. Rubenstein JL, Li J, Chen L, et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013;121(5):745–751.
- 11e. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol. 1993 Mar;11(3):561-9.
- 12e. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999 Nov;5(11):3394-402.
- 13e. Chamberlain MC, Johnston SK. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol. 2010;12(7):736–744.
- 14e. Glass J, Won M, Schultz CJ, et al. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. J Clin Oncol. 2016;34(14):1620–1625.
- 15e. Gregory G, Arumugaswamy A, Leung T, et al. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro Oncol. 2013;15(8):1068–1073.
- 16e. Holdhoff M, Ambady P, Abdelaziz A, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014;83(3):235–239.
- 17e. Bromberg JEC, Issa S, Bakunina K, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019 Feb;20(2):216-228.
- 18e. Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004 Sep 1;10(17):5643-6.
- 19e. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology. 2004 Sep 14;63(5):901-3.
- 20e. Nayak L, Abrey LE, Drappatz J, et al. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2013;54(1):58–61.



- 21e. Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011;76(10):929–930.
- 22e. Rubenstein JL, Geng H, Fraser EJ, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. ;2(13):1595–1607.
- 23e. Grommes C, Pastore A, Palaskas N, et al. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov. 2017;7(9):1018–1029.
- 24e. Makino K, Nakamura H, Hide T, Kuratsu J, et al. Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status. J Neurooncol. 2012 Jan;106(1):155-60.
- 25e. Fischer L, Thiel E, Klasen HA, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006 Jul;17(7):1141-5.
- 26e. Raizer JJ, Rademaker A, Evens AM, et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer. 2012 Aug 1;118(15):3743-8.
- 27e. Tun HW, Johnston PB, DeAngelis LM, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018;132(21):2240–2248.
- 28e. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003 Jun 1;101(11):4285-9.
- 29e. Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011 Oct 20;118(16):4363-5.
- 30e. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocytepredominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008 Jan 1;111(1):109-11.
- 31e. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015;373(25):2425–2437.
- 32e. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018 Dec 27;379(26):2517-2528.
- 33e. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012 Sep 10;30(26):3209-16.
- 34e. Michallet AS, Aktan M, Hiddemann W, et al. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018;103(4):698–706.



- 35e. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015 May 9;385(9980):1873-83.
- 36e. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101-10.
- 37e. Shanafelt TD, Wang V, Kay NE, et al. A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912). Blood. 2018;132:LBA-4.
- 38e. Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-942.
- 39e. Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011;29(10):1349–1355.
- 40e. Flinn IW, Panayiotidis P, Afanasyev B, et al. A phase 2, multicenter study investigating of atumumab and bendamustine combination in patients with untreated or relapsed CLL. Am J Hematol. 2016 Sep;91(9):900-6.
- 41e. Sharman JP, Yimer HA, Boxer M, et al. Results of a phase II multicenter study of obinutuzumab plus bendamustine in pts with previously untreated chronic lymphocytic leukemia (CLL). J Clin Oncol. 2017;35(15\_suppl):7523-7523.
- 42e. Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018 May 24;131(21):2357-2366.
- 43e. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as firstline therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007 Dec 10;25(35):5616-23.
- 44e. Castro JE, James DF, Sandoval-Sus JD, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia [published correction appears in Leukemia. 2009 Dec;23(12):2326]. Leukemia. 2009;23(10):1779–1789.
- 45e. Byrd JC, Flynn JM, Kipps TJ, et al. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016;127(1):79–86.
- 46e. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 2018; 378:1107-1120.
- 47e. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus of atumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.



- 48e. Byrd JC, Hillmen P, O'Brien SM, et al. Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study. J Clin Oncol. 2017;35(15\_suppl):7510-7510.
- 49e. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.
- 50e. Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132(23):2446–2455.
- 51e. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002 May 15;99(10):3554-61.
- 52e. Faderl S, Ferrajoli A, Wierda W, O'Brien S, Lerner S, Keating MJ. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence [published correction appears in Cancer. 2010 Aug 15;116(16):3982. Dosage error in article text]. Cancer. 2010;116(10):2360–2365.
- 53e. Robak T, Warzocha K, Govind Babu K, et al. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma. 2017 May;58(5):1084-1093.
- 54e. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008;22(11):2048–2053.
- 55e. Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2012;31(5):584–591.
- 56e. Bühler A, Wendtner CM, Kipps TJ, et al. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J. 2016;6(3):e404. Published 2016 Mar 11.
- 57e. Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study. Blood. 2017;130:498.
- 58e. Gopal AK, Davies AJ, Flinn IW, et al. Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL). Blood. 2015;126:2743.
- 59e. Cartron G, de Guibert S, Dilhuydy MS, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014: 2196-2202.
- 60e. Österborg A, Jewell RC, Padmanabhan-Iyer S, et al. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 2015;100(8):e311–e314.



- 61e. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006 Apr 1;24(10):1575-81.
- 62e. Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;19(1):65–75.
- 63e. Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18(3):297–311.
- 64e. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016 Feb;17(2):200-211.
- 65e. O'Brien S, Jones JA2, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct;17(10):1409-1418.
- 66e. Brown JR, Hillmen P, O'Brien S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2017;32(1):83–91.
- 67e. Sharman JP, Coutre SE, Furman RR, et al. Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. Blood. 2014;124:330.
- 68e. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016 Jun;17(6):768-778.
- 69e. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabinerefractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009 Aug 20;27(24):3994-4001.
- 70e. Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma. 2007 Dec;48(12):2412-7.
- 71e. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390–3397.
- 72e. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia [published correction appears in J Clin Oncol. 2010 Aug 1;28(22):3670]. J Clin Oncol. 2010;28(10):1749–1755.



- 73e. van Oers MH, Kuliczkowski K, Smolej L, et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015 Oct;16(13):1370-9.
- 74e. Langerbeins P, Busch R, Anheier N, et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014 Dec;89(12):E239-43.
- 75e. Rogers KA, Huang Y, Ruppert AS, et al. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2018 Jan;180(2):259-266.
- 76e. Tsimberidou AM, Kantarjian HM, Cortes J, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocytemacrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabinerefractory chronic lymphocytic leukemia. Cancer. 2003 Apr 1;97(7):1711-20.
- 77e. Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10;26(2):196-203.
- 78e. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203-10.
- 79e. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013 Nov 7;122(19):3276-82.
- 80e. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007 Aug 1;25(22):3344-9.
- 81e. Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):133-5.
- 82e. Furman RR, Eradat H, Switzky JC, et al. A Phase II Trial of Ofatumumab In Subjects with Waldenstrom's Macroglobulinemia. Blood. 2010;116:1795.
- 83e. Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Ann Hematol. 2018 Aug;97(8):1417-1425.



- 84e. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007 Jun 1;13(11):3320-5.
- 85e. Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol. 2014 Mar;89(3):237-42.
- 86e. Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251–3262.
- 87e. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538–1543.
- 88e. Boué F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol. 2006 Sep 1;24(25):4123-8.
- 89e. Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011 Aug;22(8):1859-64.
- 90e. Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008–3016.
- 91e. Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012;118(16):3977–3983.
- 92e. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002 Mar 1;94(5):1492-9.
- 93e. Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Jun 11;387(10036):2402-11.
- 94e. Maruyama D, Watanabe T, Maeshima AM, et al. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol. 2010 Dec;92(5):732-43.
- 95e. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 1;106(7):1569-80.



- 96e. Hoelzer D, Walewski J, Döhner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124(26):3870–3879.
- 97e. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapydependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007 Aug 1;25(22):3350-6.
- 98e. Hoffmann C, Schmid H, Müller M, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. 2011 Sep 29;118(13):3499-503.
- 99e. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014 Oct 9;124(15):2354-61.
- 100e. Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015 Aug;170(4):504-14.
- 101e. Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018 Dec;5(12):e609-e617.
- 102e. Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30(36):4462–4469. doi:10.1200/JCO.2012.41.9416
- 103e. Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013 Jun 10;31(17):2103-9.
- 104e. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015 Feb 26;125(9):1394-402.
- 105e. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015 Aug;21(8):922-6.
- 106e. van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. J Clin Oncol. 2017 Feb 10;35(5):544-551.
- 107e. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008 Oct 1;26(28):4579-86.
- 108e. Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013 Apr 20;31(12):1506-13.



- 109e. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med 2017; 377:1331-1344.
- 110e. Rosenbaum CA, Jung SH, Pitcher B, et al. Phase 2 multicentre study of single-agent of atumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). Br J Haematol. 2019 Apr;185(1):53-64.
- 111e. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and metaanalysis. J Natl Cancer Inst. 2007 May 2;99(9):706-14.
- 112e. Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N Engl J Med 2018; 379:934-947.
- 113e. Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016 Jun 23. pii: S1470-2045(16)30097-3.
- 114e. Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016 Jan;17(1):57-66.
- 115e. Dreyling M, Santoro A, Mollica L, et al. Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma. Blood. 2018; 132;1595.
- 116e. Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013 Aug 15;122(7):1137-43.
- 117e. Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximabrefractory follicular lymphoma: results from a multicenter study. Blood. 2012 Apr 19;119(16):3698-704.
- 118e. Sehn LH, Goy A, Offner FC, et al. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol. 2015;33(30):3467–3474.
- 119e. Cheson BD, Chua N, Mayer J, et al. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. J Clin Oncol. 2018 36:22, 2259-2266.
- 120e. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979-83.
- 121e. Conconi A, Martinelli G, Thiéblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5.



- 122e. Raderer M, Wohrer S, Streubel B, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology. 2006;70(6):411-7.
- 123e. Salar A, Domingo-Domenech E, Estany C, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009 Nov 15;115(22):5210-7.
- 124e. Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone Bcell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72.
- 125e. Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–2952.
- 126e. Salar A, Domingo-Domenech E, Panizo C, et al. Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-2008–01). Blood. 2012;120:3691.
- 127e. Conconi A, Martinelli G, Thiéblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5.
- 128e. Kiesewetter B, Neuper O1, Mayerhoefer ME, et al. A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. Hematol Oncol. 2018 Feb;36(1):49-55.
- 129e. Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–2232.
- 130e. Leonard JP, Trněný M, Izutsu K, et al. AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood. 2018;132:445.
- 131e. Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006 Jul 1;107(1):125-35.
- 132e. Else M, Marín-Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol. 2012 Nov;159(3):322-8.
- 133e. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003 Mar 1;21(5):891-6.
- 134e. Jones J, Andritsos L, Kreitman RJ, et al. Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study. Blood. 2016;128:1215.



- 135e. Park JH, Lee JO, Stone RM, et al. Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl. Blood. 2018;132:392.
- 136e. Tiacci E, De Carolis L, Zaja F, et al. The Chemotherapy-Free Combination of Vemurafenib and Rituximab Produces Deep and Durable Responses in Relapsed or Refractory Hairy Cell Leukemia (HCL) Patients. Blood. 2017;130:409.
- 137e. Kreitman RJ, Dearden C, Zingani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018; 32(8): 1768–1777.
- 138e. Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med 2017; 377:1250-1260
- 139e. Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016 Aug 6;388(10044):565-75.
- 140e. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005 Oct 1;23(28):7013-23.
- 141e. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005 Mar 20;23(9):1984-92.
- 142e. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007 May 2;99(9):706-14.
- 143e. Casulo C, Iannotta A, Walkley J, et al. Ofatumumab-Bendamustine As First Line Treatment for Elderly Patients with Mantle Cell Lymphoma: A Phase II Risk Adapted Design with Comprehensive Geriatric Assessment. Blood. 2014;124:1751.
- 144e. Cavalli F, Rooney B, Pei L, et al. Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT). J Clin Oncol. 2014;32(15\_suppl):8500-8500.
- 145e. Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018 Feb 17;391(10121):659-667.
- 146e. Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018;32(8):1799–1803.



- 147e. Jain P, Romaguera J, Srour SA, et al. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. 2018 Aug;182(3):404-411.
- 148e. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688–3695.
- 149e. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul;13(7):716-23.
- 150e. Davids MS, Roberts AW, Seymour JF, et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017;35(8):826–833.
- 151e. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20(3):520–525. doi:10.1093/annonc/mdn656
- 152e. Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011;117(11):2442–2451. doi:10.1002/cncr.25792
- 153e. Furtado M, Dyer MJ, Johnson R, et al. Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma--a phase II trial. Br J Haematol. 2014 May;165(4):575-8.
- 154e. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010;28(6):1038–1046.
- 155e. Morales AV, Advani R, Horwitz SM, et al. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol. 2008 Dec;59(6):953-7.
- 156e. Peñate Y, Hernández-Machín B, Pérez-Méndez LI, et al. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. Br J Dermatol. 2012 Jul;167(1):174-9.
- 157e. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–1768.
- 158e. Williams TJ, Benavides DR1, Patrice KA, et al. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. JAMA Neurol. 2016 Aug 1;73(8):928-33.
- 159e. Sehn LH, Herrera AF, Matasar MJ, et al. Polatuzumab Vedotin (Pola) Plus Bendamustine
  (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study. Blood
  2018;132:Abstract 1683.



- 160e. Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep;27(9):1902-9. doi: 10.1038/leu.2013.95.
- 161e. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019;380(23):2225-2236. doi:10.1056/NEJMoa1815281.
- 162e. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial [published correction appears in Lancet. 2020 May 30;395.
- 163e. Minard-Colin V, Auperin A, Pillon M, et al. Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. J Clin Oncol. 2016 May;34(15\_suppl):10507-10507.
- 164e. Wieduwilt MJ, Jonas BA, Schiller GJ, et al. A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401. Blood 2018:132:4018.
- 165e. Namoglu EC, Hughes ME, Plastaras JP, et al. Management and outcomes of sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman Disease). Leuk Lymphoma. 2020 Apr;61(4):905-911. doi: 10.1080/10428194.2019.1703971.
- 166e. Goekbuget N, Beck J, Brueggemann M, et al. Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL). Blood 2012;120:1493.
- 167e. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer. 2007 Nov 15;110(10):2240-7. doi: 10.1002/cncr.23032.
- 168e. Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. J Clin Oncol. 2020;38(14):1527-1538. Doi:10.1200/JCO.19.02250.
- 169e. Tiacci E, De Carolis L, Simonetti E, et al. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. N Engl J Med. 2021 May 13;384(19):1810-1823. doi: 10.1056/NEJMoa2031298.
- 170e. Park JH, Winder ES, Huntington SF, et al. First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with HCL [abstract]. Blood 2021; 138; Abstract 43.



# 171e. Magellan Rx Management. Rituximab IV Clinical Literature Review Analysis. Last updated April 2024. Accessed April 2024.

#### **Appendix 1 – Covered Diagnosis Codes**

ICD-10	Description
C79.32	Secondary malignant neoplasm of cerebral meninges
C81.00	Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site
C81.01	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.02	Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes
C81.03	Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes
C81.04	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.05	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower
C81.06	Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes
C81.07	Nodular lymphocyte predominant Hodgkin lymphoma, spleen
C81.08	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites
C81.09	Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites
C82.00	Follicular lymphoma grade I, unspecified site
C82.01	Follicular lymphoma grade I, lymph nodes of head, face and neck
C82.02	Follicular lymphoma, grade I, intrathoracic lymph nodes
C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes
C82.04	Follicular lymphoma grade I, lymph nodes of axilla and upper limb
C82.05	Follicular lymphoma grade I, lymph nodes of inguinal regional and lower limb
C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes
C82.07	Follicular lymphoma grade I, spleen
C82.08	Follicular lymphoma grade I, lymph nodes of multiple sites
C82.09	Follicular lymphoma grade I, extranodal and solid organ sites
C82.10	Follicular lymphoma grade II, unspecified site
C82.11	Follicular lymphoma grade II, lymph nodes of head, face and neck
C82.12	Follicular lymphoma, grade II, intrathoracic lymph nodes
C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes
C82.14	Follicular lymphoma grade II, lymph nodes of axilla and upper limb
C82.15	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb
C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes
C82.17	Follicular lymphoma grade II, spleen
C82.18	Follicular lymphoma grade II, lymph nodes of multiple sites
C82.19	Follicular lymphoma grade II, extranodal and solid organ sites
C82.20	Follicular lymphoma grade III, unspecified, unspecified site
C82.21	Follicular lymphoma grade III, unspecified, lymph nodes of head, face and neck
C82.22	Follicular lymphoma, grade III, unspecified, intrathoracic lymph nodes

RITUXIMAB -E- (Rituxan<sup>®</sup>, Truxima<sup>®</sup>, Ruxience<sup>®</sup>, Riabni<sup>™</sup>) Prior Auth Criteria



C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes
C82.24	Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb
C82.25	Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb
C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes
C82.27	Follicular lymphoma grade III, unspecified, spleen
C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites
C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid organ sites
C82.30	Follicular lymphoma grade IIIa, unspecified site
C82.31	Follicular lymphoma grade IIIa, lymph nodes of head, face and neck
C82.32	Follicular lymphoma, grade IIIa, intrathoracic lymph nodes
C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes
C82.34	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb
C82.35	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb
C82.36	Follicular lymphoma grade IIIa, intrapelvic lymph nodes
C82.37	Follicular lymphoma grade IIIa, spleen
C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple sites
C82.39	Follicular lymphoma grade IIIa, extranodal and solid organ sites
C82.40	Follicular lymphoma grade IIIb, unspecified site
C82.41	Follicular lymphoma grade IIIb, lymph nodes of head, face and neck
C82.42	Follicular lymphoma, grade IIIb, intrathoracic lymph nodes
C82.43	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes
C82.44	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb
C82.45	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb
C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes
C82.47	Follicular lymphoma grade IIIb, spleen
C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple sites
C82.49	Follicular lymphoma grade IIIb, extranodal and solid organ sites
C82.50	Diffuse follicle center lymphoma, unspecified site
C82.51	Diffuse follicle center lymphoma, lymph nodes of head, face and neck
C82.52	Diffuse follicle center lymphoma, intrathoracic lymph nodes
C82.53	Diffuse follicle center lymphoma, intra-abdominal lymph nodes
C82.54	Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb
C82.55	Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb
C82.56	Diffuse follicle center lymphoma, intrapelvic lymph nodes
C82.57	Diffuse follicle center lymphoma, spleen
C82.58	Diffuse follicle center lymphoma, lymph nodes of multiple sites
C82.59	Diffuse follicle center lymphoma, extranodal and solid organ sites
C82.60	Cutaneous follicle center lymphoma, unspecified site
C82.61	Cutaneous follicle center lymphoma, lymph nodes of head, face and neck
	RITUXIMAB -E- (Rituxan®, Truxima®, Ruxience®, Riabni™)
Page 53	Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval. Magellan Rx MANAGEMENT

©2024, Magellan Rx Management

C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes		
C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes		
C82.64	Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb		
C82.65	Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb		
C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes		
C82.67	Cutaneous follicle center lymphoma, spleen		
C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites		
C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites		
C82.80	Other types of follicular lymphoma, unspecified site		
C82.81	Other types of follicular lymphoma, lymph nodes of head, face and neck		
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes		
C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes		
C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb		
C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb		
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes		
C82.87	Other types of follicular lymphoma, spleen		
C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites		
C82.89	Other types of follicular lymphoma, extranodal and solid organ sites		
C82.90	Follicular lymphoma, unspecified, unspecified site		
C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face and neck		
C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes		
C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes		
C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb		
C82.95	Follicular lymphoma, unspecified lymph nodes of inguinal region and lower limb		
C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes		
C82.97	Follicular lymphoma, unspecified, spleen		
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites		
C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites		
C83.00	Small cell B-cell lymphoma, unspecified site		
C83.01	Small cell B-cell lymphoma, lymph nodes of head, face and neck		
C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes		
C83.03	Small cell B-cell lymphoma, intra-abdominal lymph nodes		
C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb		
C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb		
C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes		
C83.07	Small cell B-cell lymphoma, spleen		
C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites		
C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites		
C83.10	Mantle cell lymphoma, unspecified site		
	RITUXIMAB -E- (Rituxan®, Truxima®, Ruxience®, Riabni™)		
Page 54	Prior Auth Criteria Proprietary Information, Restricted Access – Do not disseminate or copy		
0	without approval.		

C83.11	Mantle cell lymphoma, lymph nodes of head, face and neck		
C83.12	Mantle cell lymphoma, intrathoracic lymph nodes		
C83.13	Mantle cell lymphoma, intra-abdominal lymph nodes		
C83.14	Mantle cell lymphoma, lymph nodes of axilla and upper limb		
C83.15	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb		
C83.16	Mantle cell lymphoma, intrapelvic lymph nodes		
C83.17	Mantle cell lymphoma, spleen		
C83.18	Mantle cell lymphoma, lymph nodes of multiple sites		
C83.19	Mantle cell lymphoma, extranodal and solid organ sites		
C83.30	Diffuse large B-cell lymphoma unspecified site		
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck		
C83.32	Diffuse large B-cell lymphoma intrathoracic lymph nodes		
C83.33	Diffuse large B-cell lymphoma intra-abdominal lymph nodes		
C83.34	Diffuse large B-cell lymphoma lymph nodes of axilla and upper limb		
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb		
C83.36	Diffuse large B-cell lymphoma intrapelvic lymph nodes		
C83.37	Diffuse large B-cell lymphoma, spleen		
C83.38	Diffuse large B-cell lymphoma lymph nodes of multiple sites		
C83.39	Diffuse large B-cell lymphoma extranodal and solid organ sites		
C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site		
C83.51	Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck		
C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes		
C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes		
C83.54	Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb		
C83.55	Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb		
C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes		
C83.57	Lymphoblastic (diffuse) lymphoma, spleen		
C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites		
C83.59	Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites		
C83.70	Burkitt lymphoma, unspecified site		
C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck		
C83.72	Burkitt lymphoma, intrathoracic lymph nodes		
C83.73	Burkitt lymphoma, intra-abdominal lymph nodes		
C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb		
C83.75	Burkitt lymphoma, lymph nodes of inguinal region and lower limb		
C83.76	Burkitt lymphoma, intrapelvic lymph nodes		
C83.77	Burkitt lymphoma, spleen		
C83.78	Burkitt lymphoma, lymph nodes of multiple sites		
C83.79	Burkitt lymphoma, extranodal and solid organ sites		
	RITUXIMAB -E- (Rituxan®, Truxima®, Ruxience®, Riabni™)		
Page 55	Proprietary Information. Restricted Access – Do not disseminate or copy		
-	without approval.		

©2024, Magellan Rx Management

C83.80	Other non-follicular lymphoma, unspecified site			
C83.81	Other non-follicular lymphoma, lymph nodes of head, face and neck			
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes			
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes			
C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb			
C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb			
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes			
C83.87	Other non-follicular lymphoma, spleen			
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites			
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites			
C83.90	Non-follicular (diffuse) lymphoma, unspecified site			
C83.91	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of head, face, and neck			
C83.92	Non-follicular (diffuse) lymphoma, unspecified intrathoracic lymph nodes			
C83.93	Non-follicular (diffuse) lymphoma, unspecified intra-abdominal lymph nodes			
C83.94	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of axilla and upper limb			
C83.95	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of inguinal region and lower limb			
C83.96	Non-follicular (diffuse) lymphoma, unspecified intrapelvic lymph nodes			
C83.97	Non-follicular (diffuse) lymphoma, unspecified spleen			
C83.98	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of multiple sites			
C83.99	Non-follicular (diffuse) lymphoma, unspecified extranodal and solid organ sites			
C85.10	Unspecified B-cell lymphoma, unspecified site			
C85.11	Unspecified B-cell lymphoma, lymph nodes of head, face, and neck			
C85.12	Unspecified B-cell lymphoma, intrathoracic lymph nodes			
C85.13	Unspecified B-cell lymphoma, intra-abdominal lymph nodes			
C85.14	Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb			
C85.15	Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb			
C85.16	Unspecified B-cell lymphoma, intrapelvic lymph nodes			
C85.17	Unspecified B-cell lymphoma, spleen			
C85.18	Unspecified B-cell lymphoma, lymph nodes of multiple sites			
C85.19	Unspecified B-cell lymphoma, extranodal and solid organ sites			
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site			
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face and neck			
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes			
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes			
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb			
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb			
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes			
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen			
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites			
	RITUXIMAB -E- (Rituxan®, Truxima®, Ruxience®, Riabni™)			
Page 56	Proprietary Information. Restricted Access – Do not disseminate or copy			

C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites		
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site		
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face and neck		
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes		
C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes		
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb		
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region of lower limb		
C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes		
C85.87	Other specified types of non-Hodgkin lymphoma, spleen		
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites		
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites		
C85.99	Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites		
C88.0	Waldenström macroglobulinemia		
C88.4	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma)		
C91.00	Acute lymphoblastic leukemia not having achieved remission		
C91.01	Acute lymphoblastic leukemia, in remission		
C91.02	Acute lymphoblastic leukemia, in relapse		
C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission		
C91.12	Chronic lymphocytic leukemia of B-cell type in relapse		
C91.40	Hairy cell leukemia not having achieved remission		
C91.42	Hairy cell leukemia, in relapse		
D47.Z1	Post-transplant lymphoproliferative disorder (PTLD)		
D47.Z2	Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue-Castleman		
D59.10	Autoimmune hemolytic anemia, unspecified		
D59.11	Warm autoimmune hemolytic anemia		
D59.12	Cold autoimmune hemolytic anemia		
D59.13	Mixed type autoimmune hemolytic anemia		
D59.19	Other autoimmune hemolytic anemia		
D69.3	Immune thrombocytopenic purpura		
D69.41	Evans Syndrome		
D69.42	Congenital and hereditary thrombocytopenia purpura		
D69.49	Other primary thrombocytopenia		
D89.811	Chronic graft-versus-host disease		
D89.812	Acute on chronic graft-versus-host disease		
D89.813	Graft-versus-host disease unspecified		
D89.84	IgG4-related disease		
G04.81	Other encephalitis and encephalomyelitis		
G04.89	Other myelitis		
G04.90	Encephalitis and encephalomyelitis, unspecified		
L	RITUXIMAB -E- (Rituxan®, Truxima®, Ruxience®, Riabni™)		
Page 57	Prior Auth Criteria Proprietary Information Restricted Access – Do not disseminate or conv		
	without approval.		

©2024, Magellan Rx Management

G35	Multiple sclerosis	
G36.0	Neuromyelitis optica [Devic]	
G70.0	Myasthenia gravis	
G70.00	Myasthenia gravis without (acute) exacerbation	
G70.01	Myasthenia gravis with (acute) exacerbation	
J84.9	Interstitial pulmonary disease, unspecified	
L10.0	Pemphigus vulgaris	
L13.8	Other specified bullous disorders	
L13.9	Bullous disorder, unspecified	
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	
	RITUXIMAB -E- (Rituxan®, Truxima®, Ruxience®, Riabni™) Prior Auth Criteria	
Page 58	Proprietary Information. Restricted Access – Do not disseminate or copy	

M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites
	RITUXIMAB -E- (Rituxan®, Truxima®, Ruxience®, Riabni™) Prior Auth Criteria
Page 59	Proprietary Information. Restricted Access – Do not disseminate or copy



M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip
	RITUXIMAB -E- (Rituxan®, Truxima®, Ruxience®, Riabni™) Prior Auth Criteria



M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems	
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems	
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems	
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	
	RITUXIMAB -E- (Rituxan®, Truxima®, Ruxience®, Riabni™)	



M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems			
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement			
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement			
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems			
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement			
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement			
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without orga	n or systems		
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement			
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement			
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems			
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems			
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems			
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot w	ithout organ or systems		
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement			
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site			
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder			
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder			
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder			
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow			
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow			
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow			
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist			
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist			
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist			
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand			
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand			
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand			
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip			
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip			
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip			
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee			
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee			
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee			
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot			
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot			
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and	foot		
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites			
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified			
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site			
	RITUXIMAB -E- (Rituxan®, Truxima®, Ruxience®, Riabni™) Prior Auth Critoria			
Page 62	Proprietary Information. Restricted Access – Do not disseminate or copy			

M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	
M06.8A	Other specified rheumatoid arthritis, other specified site	
M06.811	Other specified rheumatoid arthritis, right shoulder	
M06.812	Other specified rheumatoid arthritis, left shoulder	
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	
M06.821	Other specified rheumatoid arthritis, right elbow	
M06.822	Other specified rheumatoid arthritis, left elbow	
M06.829	Other specified rheumatoid arthritis, unspecified elbow	
M06.831	Other specified rheumatoid arthritis, right wrist	
M06.832	Other specified rheumatoid arthritis, left wrist	
M06.839	Other specified rheumatoid arthritis, unspecified wrist	
M06.841	Other specified rheumatoid arthritis, right hand	
M06.842	Other specified rheumatoid arthritis, left hand	
M06.849	Other specified rheumatoid arthritis, unspecified hand	
M06.851	Other specified rheumatoid arthritis, right hip	
M06.852	Other specified rheumatoid arthritis, left hip	
M06.859	Other specified rheumatoid arthritis, unspecified hip	
	RITUXIMAB -E- (Rituxan®, Truxima®, Ruxience®, Riabni™) Prior Auth Criteria	
Page 63	Proprietary Information. Restricted Access – Do not disseminate or copy	

M06.869	Other specified rheumatoid arthritis, unspecified knee	
M06.871	Other specified rheumatoid arthritis, right ankle and foot	
M06.872	Other specified rheumatoid arthritis, left ankle and foot	
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	
M06.88	Other specified rheumatoid arthritis, vertebrae	
M06.89	Other specified rheumatoid arthritis, multiple sites	
M06.9	Rheumatoid arthritis, unspecified	
M32.14	Glomerular disease in systemic lupus erythematosus	
M31.10	Thrombotic microangiopathy, unspecified	
M31.30	Wegener's granulomatosis without renal involvement	
M31.31	Wegener's granulomatosis with renal involvement	
M31.7	Microscopic polyangiitis	
M32.10	Systemic lupus erythematosus organ or system involvement unspecified	
M32.11	Endocarditis in systemic lupus erythematosus	
M32.12	Pericarditis in systemic lupus erythematosus	
M32.13	Lung involvement in systemic lupus erythematosus	
M32.14	Glomerular disease in systemic lupus erythematosus	
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	
M32.19	Other organ or system involvement in systemic lupus erythematosus	
M32.8	Other forms of systemic lupus erythematosus	
M32.9	Systemic lupus erythematosus, unspecified	
M60.80	Other myositis, unspecified site	
M60.811	Other myositis, right shoulder	
M60.812	Other myositis, left shoulder	
M60.819	Other myositis, unspecified shoulder	
M60.821	Other myositis, right upper arm	
M60.822	Other myositis, left upper arm	
M60.829	Other myositis, unspecified upper arm	
M60.831	Other myositis, right forearm	
M60.832	Other myositis, left forearm	
M60.839	Other myositis, unspecified forearm	
M60.841	Other myositis, right hand	
M60.842	Other myositis, left hand	
M60.849	Other myositis, unspecified hand	
M60.851	Other myositis, right thigh	
M60.852	Other myositis, left thigh	
M60.859	Other myositis, unspecified thigh	
	RITUXIMAB -E- (Rituxan <sup>®</sup> , Truxima <sup>®</sup> , Ruxience <sup>®</sup> , Riabni™)	
Page 64	Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy	MagellanRx
-		

M60.861	Other myositis, right lower leg
M60.862	Other myositis, left lower leg
M60.869	Other myositis, unspecified lower leg
M60.871	Other myositis, right ankle and foot
M60.872	Other myositis, left ankle and foot
M60.879	Other myositis, unspecified ankle and foot
M60.88	Other myositis, other site
M60.89	Other myositis, multiple sites
M79.10	Myalgia, unspecified site
M79.11	Myalgia of mastication muscle
M79.12	Myalgia of auxiliary muscles, head and neck
M79.18	Myalgia, other site
N04.0	Nephrotic syndrome with minor glomerular abnormality
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis
N04.21	Primary membranous nephropathy with nephrotic syndrome
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis
N04.6	Nephrotic syndrome with dense deposit disease
N04.621	Primary membranous nephropathy with isolated proteinuria
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis
N04.8	Nephrotic syndrome with other morphologic changes
N04.9	Nephrotic syndrome with unspecified morphologic changes
T86.09	Other complications of bone marrow transplant
Z85.71	Personal history of Hodgkin lymphoma
Z85.72	Personal history of non-Hodgkin lymphomas
Z85.79	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues
Z94.81	Bone marrow transplant status
Z94.89	Other transplanted organ and tissue status
Z94.9	Transplanted organ and tissue status, unspecified

# Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The



following link may be used to search for NCD, LCD, or LCA documents: <u>https://www.cms.gov/medicare-coverage-database/search.aspx</u>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes			
Jurisdiction	NCD/LCA/LCD Document (s)	Contractor	
5,8	A55639	Wisconsin Physicians Service Insurance Corp (WPS)	
15	A57160, A58582	CGS Administrators, LLC	
6,K	A59101	National Government Services, Inc	
J,M	A56380	Palmetto GBA	

Medicare Part B Administrative Contractor (MAC) Jurisdictions				
Jurisdiction	Applicable State/US Territory	Contractor		
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC		
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC		
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)		
6	MN, WI, IL	National Government Services, Inc. (NGS)		
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.		
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)		
N (9)	FL, PR, VI	First Coast Service Options, Inc.		
J (10)	TN, GA, AL	Palmetto GBA		
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA		
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in	Novitas Solutions, Inc.		
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)		
15	KY, OH	CGS Administrators, LLC		

Page 66

